Systematic Review

Association between Endotype of Prematurity and Mortality: A Systematic Review, Meta-analysis and Meta-regression

Tamara M Hundscheid ^a, Eduardo Villamor-Martinez ^b, Eduardo Villamor ^a

^a Department of Pediatrics, Maastricht University Medical Center (MUMC+), School for Oncology and Reproduction (GROW), Maastricht, the Netherlands.

^b Statistics Netherlands, 6412HX Heerlen, the Netherlands.

Short Title: Association between Endotype of Prematurity and Mortality

Corresponding Author:

Eduardo Villamor

Department of Pediatrics

Maastricht University Medical Center (MUMC+)

Postbus 5800

6202 AZ Maastricht, the Netherlands

Tel: 003143-3877246

E-mail: e.villamor@mumc.nl

Number of Tables: 1

Number of Figures: 3

Word count: 3486

Keywords: preterm birth, chorioamnionitis, hypertensive disorders of pregnancy, growth restriction,

mortality

, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

1 Abstract

2 **Introduction** Preterm birth represents the leading cause of neonatal mortality.

- 3 Pathophysiological pathways, or endotypes, leading to prematurity can be clustered into
- 4 infection/inflammation and dysfunctional placentation. We aimed to perform a systematic
- 5 review and meta-analysis exploring the association between these endotypes and risk of
- 6 mortality during first hospital admission.

7 Methods PROSPERO ID: CRD42020184843. PubMed and Embase were searched for

- 8 observational studies examining infants with gestational age (GA) \leq 34 weeks.
- 9 Chorioamnionitis represented the infectious-inflammatory endotype, while dysfunctional
- 10 placentation proxies were hypertensive disorders of pregnancy (HDP) and small for GA
- 11 (SGA)/intrauterine growth restriction (IUGR). A random-effects model was used to calculate
- 12 odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity was studied using
- 13 random-effects meta-regression analysis.
- 14 Results Of 4322 potentially relevant studies, 150 (612,580 infants) were included. Meta-
- analysis showed a positive mortality odds for chorioamnionitis (OR 1.43, 95% CI 1.25-1.62)
- and SGA/IUGR (OR 1.68, 95% CI 1.38-2.04), but a negative mortality odds for HDP (OR 0.74,
- 17 95% CI 0.64-0.86). Chorioamnionitis was associated with a lower GA, while HDP and
- 18 SGA/IUGR were associated with a higher GA. Meta-regression showed a significant
- 19 correlation between these differences in GA and mortality odds.
- 20

Discussion/Conclusion Our data suggest that the infectious/inflammatory endotype of
 prematurity has a greater overall impact on mortality risk as it is the most frequent
 endotype in the lower GAs. However, when the endotype of placental dysfunction is severe
 enough to induce growth restriction, it is strongly associated with higher mortality rates
 even though newborns are more mature.

26

27 Introduction

Preterm birth is defined by the World Health Organization as delivery before 37 completed weeks of
gestational age (GA) and is further subdivided into extreme (less than 28 weeks), very (28 to less than
32 weeks) moderate (32 to less than 34 weeks), and late (34 to less than 37 weeks) preterm birth.
Although survival has increased substantially in the last few decades, preterm birth and its associated
complications represent the leading cause of both neonatal and childhood mortality worldwide (1-3).
Although GA is the main prognostic factor in prematurity, there is growing recognition that the
pathological conditions triggering preterm birth play a central role in the development of its

35 complications (4-8). McElrath et al. proposed two main pathways to extreme preterm birth: 1)

36 infection/inflammation and 2) dysfunctional placentation. The first group include chorioamnionitis,

37 pre-labor premature rupture of membranes, placental abruption, and cervical insufficiency (9). The

38 second group is characterized by the presence of histologic features of placental vascular dysfunction

39 and is associated with hypertensive disorders of pregnancy (HDP) and the entity identified as fetal

40 indication/intrauterine growth restriction (IUGR) (9). These two etiological pathways possess the

41 characteristics to be considered as the main endotypes of very and extreme preterm birth (4, 7).

The term endotype refers to "a subtype of a condition, which is defined by a distinct functional or pathophysiological mechanism."(10). Endotypes are thus a different form of classification from clinical phenotypes and describe distinct disease entities with a defining etiology and/or a consistent pathophysiological mechanism. In line with the approach of personalized medicine, endotyping will facilitate the design of more targeted therapeutic and prognostic approaches (4, 11-14).

47 Despite the growing awareness about the role of the pathophysiologic mechanism, or endotype, 48 triggering prematurity in its outcome (4-7, 15-19), this variable is rarely taken into account in the 49 models predicting mortality in the preterm newborn (20-22). Furthermore, to the best of our 50 knowledge, the association between the endotype of prematurity and mortality during primary 51 hospital admission has not been systematically reviewed. The purpose of the present study was to 52 address this gap in the literature. Following the methodology described in our previous metaanalyses (7, 23), the infectious-inflammatory endotype was represented by chorioamnionitis, while 53 54 the dysfunctional placentation endotype was represented by HDP and IUGR. Since many researchers 55 use small for gestational age (SGA) as a proxy for IUGR, and although the two conditions are not 56 necessarily synonymous (24-27), we also collected data on SGA. From now on, this group will be 57 referred to as SGA/IUGR. In addition, through the use of meta-regression, we aimed to unravel the

- role of variables such as GA, infant sex, or use of antenatal corticosteroids in the association between
- 59 endotype of prematurity and mortality.

60 Methods

- 61 The study was conducted according to the PRISMA and MOOSE guidelines. Detailed information on
- 62 methods is provided as supplementary material. Review protocol was registered in PROSPERO
- 63 database (ID= CRD42020184843). The Population, Exposure, Comparison and Outcome (PECO)
- 64 question was: Do preterm infants (P) exposed to chorioamnionitis, HDP, or growth restriction during
- 65 pregnancy (E) have a higher risk of mortality (O) than preterm infants with no history of exposure
- 66 (C)?

67 Sources and search strategy

- 68 A comprehensive literature search was undertaken using the PubMed and EMBASE from their
- 69 inception up to March 2022. Search strategy is detailed in the supplementary material.

70 Study selection

- 71 Studies were included if they examined extreme to moderate preterm infants(GA ≤34 weeks and/or
- birth weight ≤1500 gram) and reported primary data that could be used to measure the association
- 73 between exposure to CA, HDP or SGA/IUGR and mortality before hospital discharge.
- 74 Data extraction, definitions, and quality assessment

Two investigators (TH, EV-M) independently extracted data from relevant studies using a predetermined data extraction form. Any definition of chorioamnionitis, HDP or SGA/IUGR was accepted but we performed sub-group analysis based on the different definitions. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS) for cohort or case-control studies (28).

79 Statistical analysis

Studies were combined and analyzed using COMPREHENSIVE META-ANALYSIS V3.0 software (Biostat Inc., Englewood, NJ, USA). Summary statistics were calculated with a random-effects model and subgroups were combined with a mixed-effects model (29). For dichotomous outcomes, the odds ratio (OR) with 95% confidence interval (CI) was calculated. For continuous outcomes, the mean difference (MD) with 95% CI was calculated. Statistical heterogeneity was assessed by Cochran's Q statistic and by the I² statistic. Potential sources of heterogeneity were assessed through subgroup analysis and/or random effects (method of moments), univariate meta-regression analysis (30). We used the Egger's

regression test and funnel plots to assess publication bias. A probability value of less than 0.05 (0.10
for heterogeneity) was considered statistically significant.

89 **Results**

90 The PRISMA flow diagram of the search process is shown in eFigure 1 in the Supplement. Of 4322

91 potentially relevant studies, 150 met the inclusion criteria. These studies included 612,580 infants.

92 Characteristics of the studies and quality assessment are summarized in eTable 1 in the Supplement.

93 All studies received a NOS score of at least six points, indicating a low to moderate risk of bias.

94

95 Main meta-analyses

96 Meta-analysis showed a significant association between chorioamnionitis and increased odds of 97 mortality (Fig. 1, eFig. 2 in the Supplement). Heterogeneity was moderate (Fig. 1). When subdividing 98 by chorioamnionitis definition, the association with mortality remained significant for both clinical and 99 histological chorioamnionitis. Meta-regression did not show significant differences depending on 100 choriomanionitis definition (P=0.375). When the meta-analysis was limited to the subgroup of infants 101 with GA<28 weeks, no significant association between choriomanonitis and mortality was observed (Fig. 2, eFig. 3 in the Supplement). Meta-regression showed significant differences (P=0.021) between 102 103 studies that only included infants with GA≤28 weeks and those that also included older infants (eTable 104 2 in the Supplement).

105 Meta-analysis showed a significant association between HDP and decreased odds of mortality (Fig. 1, 106 eFig. 4 in the Supplement). Heterogeneity was moderate (Fig. 1). When subdividing by HDP definition, 107 the association with mortality remained significant for any HDP and preeclampsia but not for 108 preeclampsia/HELLP. Meta-regression showed a significant difference (P=0.013) between the ORs for 109 any HDP and preeclampsia. When the meta-analysis was limited to the subgroup of infants with GA≤28 110 weeks, no significant association between HDP and mortality was observed (Fig. 2, eFig. 5 in the 111 Supplement). Meta-regression showed significant differences (P<0.001) between studies that only 112 included infants with GA<28 weeks and those that also included older infants (eTable 2 in the Supplement). 113

Meta-analysis showed a significant association between SGA/IUGR and increased odds of mortality (Fig. 1, eFig. 6 in the Supplement). Heterogeneity was high (Fig. 1). When subdividing by definition of SGA/IUGR, the association with mortality remained significant for the three thresholds of birth weight (BW <P10, <P5, and <P3), but not for IUGR (Fig. 1). Meta-regression analysis did not show significant differences in the association between SGA/IUGR and mortality depending on the criteria used to

- define SGA/IUGR (P=0.783). The association between SGA/IUGR and increased odds of mortality was
- also observed when the meta-analysis was limited to the subgroup of infants with GA≤28 weeks (Fig.
- 121 2, eFig. 7 in the Supplement).
- 122 Neither visual inspection nor Egger's test suggested the presence of publication or selection bias for
- the chorioamnionitis (P=0.394) and SGA/IUGR (P=0.554) meta-analyses (eFig. 8 in the Supplement). In
- 124 contrast, a slight publication bias was observed in the HDP meta-analysis (P=0.016).

125 Additional meta-analyses, sensitivity analysis and meta-regression

To investigate the potential sources of heterogeneity, we conducted additional meta-analyses exploring the differences in baseline characteristics (GA, sex, and exposure to antenatal corticosteroids) between the groups exposed and non-exposed to chorioamnionitis, HDP, or SGA/IUGR. We also performed meta-regression and subgroup analysis.

130 Infants exposed to chorioamnionitis had a significantly lower GA than infants not exposed to the 131 condition, while infants exposed to HDP or belonging to the SGA/IUGR group had a higher GA than 132 their respective controls (Table 1). Meta-regression showed that these differences in GA significantly 133 correlated with the effect size of the association between mortality and chorioamnionitis, HDP, or 134 SGA/IUGR (Fig. 3, eTable 3 in the Supplement).

To further assess the effect of GA on the meta-analyses, we carried out a subgroup analysis of studies where the difference in GA between infants exposed to the chorioamnionitis, HDP, or SGA/IUGR and their respective controls was not statistically significant (p>0.05). In these subgroups of studies, neither chorioamnionitis nor HDP were significantly associated with mortality odds, but the association between SGA/IUGR and higher odds of mortality was maintained (eTable 4 in the Supplement).

- 140 Chorioamnionitis, HDP and SGA/IUGR were all associated with a higher odds of exposure to
- 141 antenatal corticosteroids compared to their respective control groups (eTable 6 in the Supplement).
- 142 Exposure to HDP was negatively associated with male sex (Table 1). As expected, exposure to
- 143 chorioamnionitis was negatively associated with exposure to HDP or being SGA/IUGR and a strong
- 144 positive association was observed between HDP and SGA (Table 1).
- 145 We also analyzed the possible effect of study design, median year in which the study was conducted,
- and geographical location (continent) on the results of the meta-analysis. Meta-regression showed
- 147 no significant differences when studies were grouped based on whether they were prospective or
- 148 retrospective (eTable 2 in the Supplement). When cohort and case-control studies were compared, a
- significant difference was observed for the HDP meta-analysis (P=0.030), but not for the meta-

analyses on chorioamnionitis or SGA/IUGR (eTable 2 in the Supplement). Meta-regression did not
show a significant correlation between the median year in which the studies were conducted and the
effect size of the association between mortality and chorioamnionitis, HDP, or SGA/IUGR (eTable 3 in
the Supplement). In addition, meta-regression also showed no significant differences when studies
were grouped according to whether the inclusion of infants took place before or after the year 2000
(eTable 2 in the Supplement). Finally, meta-regression showed no significant differences when the
studies were grouped by continent (eTable 5 in the Supplement).

157 Discussion/Conclusion

158 This is the first systematic review and meta-analysis that comprehensively addresses the association between endotype of prematurity and mortality during first hospital admission. Meta-analysis 159 showed an association between the inflammatory/infectious endotype, represented by 160 161 chorioamnionitis, and increased odds of mortality. In contrast, meta-analysis of the two proxies of 162 the placental dysfunction endotype showed diametrically opposite results; HDP were associated with 163 decreased odds while SGA/IUGR was associated with positive odds of mortality. Interestingly, when 164 analysis was restricted to extremely preterm infants, only the association between SGA/IUGR and 165 mortality remained significant. In addition, our results confirm that conditions triggering prematurity 166 differ in important characteristics that may play a relevant role in mortality risk. Chorioamnionitis was associated with lower GA and higher exposure to antenatal corticosteroids, while HDP and 167 168 SGA/IUGR were associated with higher GA. Meta-regression demonstrated a significant correlation 169 between these differences in GA and the effect size of the association between mortality and 170 endotype. Meta-regression also showed that the association between endotype of prematurity and 171 mortality is relatively homogeneous across continents and has not changed significantly over the 172 years.

173 Since very and extremely preterm birth is by definition a pathological condition, there is no healthy 174 control group with which to compare infants exposed to a given prenatal insult (4, 5, 9, 31). Although 175 some placentas may combine lesions of infection/inflammation and vascular dysfunction (32), 176 fetuses exposed to chorioamnionitis will be less likely exposed to HDP and vice versa (4, 5, 9, 31). The main originality of our meta-analysis lies in the comparison of the three pathological conditions most 177 frequently associated with preterm birth. However, both our identification of the two endotypes and 178 179 the validity of chorioamnionitis, HDP and SGA/IUGR as their proxies may be questionable. Moreover, 180 there is great heterogeneity in the potential clinical applicability of these three proxies. For example,

histological chorioamnionitis may be a good indicator of the presence of the infectious endotype, butinformation about its presence may be not available at birth (8).

183 Regarding the endotype of placental dysfunction, the criteria for the diagnosis of HDP have been changing over the years and even those on which there is greater consensus may be far from being 184 185 implemented worldwide (33). Finally, the most questionable assumption of our study may be the use of SGA as proxy for placental dysfunction. SGA is a statistical definition based on BW, with the 10th 186 187 percentile as the most commonly used threshold (26, 34, 35). Therefore, SGA definition also 188 encompasses constitutionally small infants who do not suffer growth restriction. Conversely, growth restricted infants who have a BW above the 10th percentile may be misclassified as normally grown 189 (26). It has been suggested that a cutoff value below the 5th or 3rd percentile may reflect a degree of 190 191 smallness that is more likely to be pathologic rather than constitutional (26, 36). However, even this 192 pathology may be of fetal origin as there are conditions in which restricted growth is not caused

- 193 primarily by placental insufficiency, but indirectly leads to it (37).
- 194

195 Regardless of its specificity as a marker of placental dysfunction, our data confirmed that SGA 196 preterm infants are at increased risk of death. The association between mortality and SGA was observed even for the most conservative threshold (10th percentile). Preterm SGA infants add to their 197 198 immaturity the technical challenges of their small size that complicate procedures such as 199 endotracheal intubation or vascular access (38, 39). Of note, the meta-analysis could not 200 demonstrate a significant association between mortality and growth restriction based on fetal 201 assessment. However, this analysis was based on very few studies that showed a high degree of 202 heterogeneity. Damodaram et al. conducted a meta-analysis in which cohorts of growth-restricted 203 preterm infants were compared with cohorts of infants with normal growth and found a marked 204 increase in mortality across all GAs (19).

205 A common conundrum in perinatal medicine is the extent to which complications of pregnancy harm 206 preterm infants through triggering prematurity or through disturbances in fetal homeostasis and 207 development (4, 40). In the last few years, we conducted meta-analyses on the association between 208 chorioamnionitis and complications of prematurity such as bronchopulmonary dysplasia (23), 209 retinopathy of prematurity (41), intraventricular hemorrhage (42), sepsis (43), or patent ductus 210 arteriosus (44). Similar to the present findings, meta-analyses showed an association between 211 chorioamnionitis and all these conditions (23, 41-44). In addition, meta-regression analysis showed a 212 correlation between the earlier GA of the chorioamnionitis-exposed infants and the risk of 213 developing the above-mentioned complications (23, 41-44). These data suggest that a significant

component of the pathologic effect of chorioamnionitis is related to lower GA of the infants rather

215 than to the inflammatory stress that generates in the fetus.

216 In contrast to what we observed for chorioamnionitis and for SGA/IUGR, exposure to HDP was 217 associated with lower odds of mortality in the newborn. Placental dysfunction is a multifactorial 218 condition, with fetuses becoming hypoxemic, undernourished, and hypercortisolemic, each of these 219 variables being capable of independently affecting fetal homeostasis and development (45). Our 220 results suggest that when placental dysfunction does not significantly affect birth weight, preterm 221 newborns may be in more favorable conditions to cope with extrauterine life. However, it cannot be 222 overlooked that HDP-exposed infants had a higher GA and were more often girls, which may have 223 contributed to the lower mortality (46).

224 Even among infants of comparable GA at delivery, the endotype of prematurity may be a 225 determining factor in the time and cause of death. Most deaths in extreme preterm infants occur in 226 the first days of life as a consequence of pulmonary immaturity (6, 47). It is noteworthy that the 227 intrauterine stresses associated with both the infectious/inflammatory endotype and the placental 228 dysfunction endotype have been considered as inducers of pulmonary maturity, leading to a lower 229 rate of respiratory distress at birth (48, 49). Although very limited by the clinical and statistical 230 heterogeneity, the results of our previous meta-analyses suggest that the lower incidence of 231 respiratory distress is observed only in the SGA/IUGR group (7, 23). Nevertheless, other conditions 232 such as pulmonary hemorrhage or pulmonary hypertension may contribute to increased early 233 respiratory mortality in SGA infants (6, 47).

234 Severe intraventricular hemorrhage (IVH) is another major cause of early mortality among extremely 235 preterm infants (6, 47, 50). As mentioned above, in a previous meta-analysis we observed an 236 association between chorioamnionitis and the risk of developing IVH (42). Interestingly, this 237 association was independent on the effect of chorioamnionitis on GA (42). It is therefore likely that a part of the early mortality induced by chorioamnionitis is related to clinical instability that may 238 increase the chances of developing severe IVH. Conversely, and although to our knowledge this has 239 240 not been systematically reviewed, several cohort studies suggest that exposure to HDP or being SGA 241 may be associated with a lower risk of developing severe IVH (6, 47, 51, 52).

An important limitation of our study is the moderate to high heterogeneity that we found in most of the meta-analyses. Through subgroup analysis and meta-regression, we aimed to investigate possible sources of heterogeneity. Neither the association between chorioamnionitis and high odds of mortality nor the association HDP and reduced odds of mortality were observed in the subgroup of

246 studies that exclusively included extremely preterm infants (GA ≤28 weeks). In contrast, the

- association between SGA/IUGR and high odds of mortality was maintained in the subgroup of
- 248 extremely preterm infants. Together, these data suggest that at lower GAs mortality is relatively
- 249 independent of the endotype of prematurity. However, infants who combine extreme prematurity
- and being SGA would have the highest mortality risk.

Another limitation of our meta-analyses is that they are based on a 'births-based' instead of 'fetusesat-risk' formulation (53, 54). Fetuses who would be viable but die *in utero* are not considered when assessing mortality from a births-based perspective (53, 54). Therefore, if we intend to analyze the overall impact of an endotype of prematurity on perinatal health, we should also consider how many children are not born prematurely because they die as a result of the severely adverse intrauterine environment that is induced by their particular endotype.

257 Advances in perinatology over the past two decades, such as wide implementation of antenatal 258 steroids and surfactant, have changed care for extremely preterm infants and have been associated 259 with a decrease in mortality (55). However, neither meta-regression nor division of studies into two subgroups (median year of the cohort before or after 2000) could demonstrate an effect of study 260 261 date on the association between endotype of prematurity and mortality. Finally, it is interesting to 262 note our finding that in the three groups analyzed (chorioamnionitis, HDP and SGA/IUGR) the odds of 263 receiving antenatal corticosteroids was higher than that of the respective controls. We speculate that 264 this finding may be related to the more heterogeneous nature of the control groups. Nevertheless, 265 our group is conducting a meta-analysis on the association between antenatal corticosteroids and 266 endotype of prematurity.

267 In summary, the present data suggest that the infectious/inflammatory endotype of prematurity has 268 a greater overall impact on mortality risk as it is the most frequent endotype in the lower and more vulnerable gestational ages. However, when the endotype of placental dysfunction is severe enough 269 270 to induce growth restriction, it is strongly associated with higher mortality rates even though 271 newborns are more mature. Nevertheless, neither of the two endotypes is desirable and extremely 272 preterm birth should be prevented regardless of the etiopathogenic process that caused it. However, 273 delay in delivery may not benefit some infants if prematurity is triggered by a severe pathology and 274 postponement of delivery is not adequately addressing the underlying condition (15). Finally, since 275 some placental diagnoses may be critical for personalized clinical care of extremely preterm 276 newborns, efforts should be made to have information on placental pathology available in the first 277 days of life (8, 32).

278 Statement of Ethics

- 279 As this systematic review and meta-analysis did not involve animal subjects or personally identifiable
- 280 information on human subjects, ethics review board approval and patient consent were not
- 281 required.

282 Conflict of Interest Statement

- 283 The authors declare no conflict of interest. The views expressed in this paper are those of the authors
- and do not necessarily reflect the policies of Statistics Netherlands.

285 Funding Sources

- 286 This research did not receive any specific grant from any funding agency in the public, commercial or
- 287 not-for-profit sectors.

288 Author Contributions

- 289 EV conceived and designed the study with input from the other authors. TH and EV-M designed and
- 290 executed the literature search, screened and reviewed the search results and abstracted the data. EV
- 291 checked data extraction for accuracy and completeness. TH and EV-M assessed the quality of the
- included studies. TH conducted the analysis with input from EV. All authors contributed to the
- 293 interpretation of analysis. TH and EV made the figures and tables. TH and EV drafted the manuscript
- 294 with input from the other authors. All authors reviewed the manuscript and provided important
- intellectual content. TH and EV take responsibility for the article as a whole.

296 Data Availability Statement

- All data relevant to the study are included in the article or uploaded as supplementary information.
- 298 Additional data are available upon reasonable request.

299 **References**

1. Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller A-B, et al. Born Too Soon: The global epidemiology of 15 million preterm births. Reproduc Health. 2013;10(1):S2.

2. Harrison MS, Goldenberg RL. Global burden of prematurity. Semin Fetal Neonatal Med. 2016;21(2):74-9.

3. Raju TN, Buist AS, Blaisdell CJ, Moxey-Mims M, Saigal S. Adults born preterm: a review of general health and system-specific outcomes. Acta Paediatr. 2017;106(9):1409-37.

4. Pierro M, Van Mechelen K, van Westering-Kroon E, Villamor-Martínez E, Villamor E. Endotypes of Prematurity and Phenotypes of Bronchopulmonary Dysplasia: Toward Personalized Neonatology. J Pers Med. 2022;12(5):687.

5. Gagliardi L, Rusconi F, Da Frè M, Mello G, Carnielli V, Di Lallo D, et al. Pregnancy disorders leading to very preterm birth influence neonatal outcomes: results of the population-based ACTION cohort study. Pediatr Res. 2013;73(6):794-801.

6. Corchia C, Ferrante P, Da Frè M, Di Lallo D, Gagliardi L, Carnielli V, et al. Cause-specific mortality of very preterm infants and antenatal events. J Pediatr. 2013;162(6):1125-32. e4.

7. Pierro M, Villamor-Martinez E, van Westering-Kroon E, Alvarez-Fuente M, Abman SH, Villamor E. Association of the dysfunctional placentation endotype of prematurity with bronchopulmonary dysplasia: a systematic review, meta-analysis and meta-regression. Thorax. 2021.

8. Redline RW, Ravishankar S, Bagby CM, Saab ST, Zarei S. Four major patterns of placental injury: a stepwise guide for understanding and implementing the 2016 Amsterdam consensus. Mod Pathol. 2021;34(6):1074-92.

9. McElrath TF, Hecht JL, Dammann O, Boggess K, Onderdonk A, Markenson G, et al. Pregnancy disorders that lead to delivery before the 28th week of gestation: an epidemiologic approach to classification. Am J Epidemiol. 2008;168(9):980-9.

10. Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-60.

11. Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care. 2020;43(1):5-12.

12. Malhotra A, Mesarwi O, Pepin J-L, Owens RL. Endotypes and phenotypes in obstructive sleep apnea. Curr Opin Pulm Med. 2020;26(6):609.

13. Cardell L-O, Stjärne P, Jonstam K, Bachert C. Endotypes of chronic rhinosinusitis: Impact on management. J Allergy Clin Immunol. 2020;145(3):752-6.

14. Wong HR, Sweeney TE, Lindsell CJ. Simplification of a septic shock endotyping strategy for clinical application. Am J Respir Crit Care Med. 2017;195(2):263-5.

15. Basso O, Wilcox A. Mortality risk among preterm babies: immaturity vs. underlying pathology. Epidemiology. 2010;21(4):521.

16. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am J Obstet Gynecol. 2004;191(2):481-7.

17. Zaki D, Balayla J, Beltempo M, Gazil G, Nuyt AM, Boucoiran I. Interaction of chorioamnionitis at term with maternal, fetal and obstetrical factors as predictors of neonatal mortality: a population-based cohort study. BMC Pregnancy Childbirth. 2020;20(1):454.

18. Ferrazzani S, Luciano R, Garofalo S, D'Andrea V, De Carolis S, De Carolis MP, et al. Neonatal outcome in hypertensive disorders of pregnancy. Early Hum Dev. 2011;87(6):445-9.

19. Damodaram M, Story L, Kulinskaya E, Rutherford M, Kumar S. Early adverse perinatal

complications in preterm growth-restricted fetuses. Aust N Z J Obstet Gynaecol. 2011;51(3):204-9.

20. McLeod JS, Menon A, Matusko N, Weiner GM, Gadepalli SK, Barks J, et al. Comparing mortality risk models in VLBW and preterm infants: systematic review and meta-analysis. J Perinatol. 2020;40(5):695-703.

21. van Beek PE, Andriessen P, Onland W, Schuit E. Prognostic Models Predicting Mortality in Preterm Infants: Systematic Review and Meta-analysis. Pediatrics. 2021;147(5).

22. Iriondo M, Thio M, Del Río R, Baucells BJ, Bosio M, Figueras-Aloy J. Prediction of mortality in very low birth weight neonates in Spain. PLoS One. 2020;15(7):e0235794.

23. Villamor-Martinez E, Álvarez-Fuente M, Ghazi AM, Degraeuwe P, Zimmermann LJ, Kramer BW, et al. Association of chorioamnionitis with bronchopulmonary dysplasia among preterm infants: a systematic review, meta-analysis, and meta-regression. JAMA Netw Open. 2019;2(11):e1914611-e.
24. Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance,

diagnosis, and management. Am J Obstet Gynecol. 2011;204(4):288-300. 25. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol.

2016;48(3):333-9.

26. Beune IM, Bloomfield FH, Ganzevoort W, Embleton ND, Rozance PJ, van Wassenaer-LeemhuisAG, et al. Consensus Based Definition of Growth Restriction in the Newborn. J Pediatr. 2018;196:71-6. e1.

27. Monier I, Ancel PY, Ego A, Jarreau PH, Lebeaux C, Kaminski M, et al. Fetal and neonatal outcomes of preterm infants born before 32 weeks of gestation according to antenatal vs postnatal assessments of restricted growth. Am J Obstet Gynecol. 2017;216(5):516 e1- e10.
28. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. Newcastle-Ottawa quality

assessment scale cohort studies. University of Ottawa. 2014.

29. Borenstein M, Higgins J. Meta-analysis and subgroups. Prev Sci. 2013;14(2):134-43.

30. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis: John Wiley & Sons; 2021.

31. Williams TC, Bach CC, Matthiesen NB, Henriksen TB, Gagliardi L. Directed acyclic graphs: a tool for causal studies in paediatrics. Pediatr Res. 2018;84(4):487-93.

32. Mir IN, Leon R, Chalak LF. Placental origins of neonatal diseases: toward a precision medicine approach. Pediatr Res. 2021;89(2):377-83.

33. Tranquilli A, Dekker G, Magee L, Roberts J, Sibai B, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97-104.

34. Xu H, Simonet F, Luo ZC. Optimal birth weight percentile cut-offs in defining small-or large-forgestational-age. Acta Paediatr. 2010;99(4):550-5.

35. Zeve D, Regelmann MO, Holzman IR, Rapaport R. Small at birth, but how small? The definition of SGA revisited. Horm Res Paediatr. 2016;86(5):357-60.

36. Ray JG, Park AL, Fell DB. Mortality in infants affected by preterm birth and severe small-forgestational age birth weight. Pediatrics. 2017;140(6).

37. Hendrix N, Berghella V. Non-placental causes of intrauterine growth restriction. Semin Perinatol.2008;32(3):161-5.

38. Haile D, Suominen P. Technologies in pediatric vascular access: have we improved success rate in peripheral vein cannulation? Acta Anaesthesiol Scand. 2017;61(7):710-3.

39. Miller KE, Singh N. Association of multiple tracheal intubation attempts with clinical outcomes in extremely preterm infants: a retrospective single-center cohort study. J Perinatol. 2022:1-5.

40. Wilcox AJ, Weinberg CR, Basso O. On the pitfalls of adjusting for gestational age at birth. Am J Epidemiol. 2011;174(9):1062-8.

41. Villamor-Martinez E, Cavallaro G, Raffaeli G, Mohammed Rahim OM, Gulden S, Ghazi AM, et al. Chorioamnionitis as a risk factor for retinopathy of prematurity: An updated systematic review and meta-analysis. PLoS One. 2018;13(10):e0205838.

42. Villamor-Martinez E, Fumagalli M, Mohammed Rahim O, Passera S, Cavallaro G, Degraeuwe P, et al. Chorioamnionitis is a risk factor for intraventricular hemorrhage in preterm infants: a systematic review and meta-analysis. Front Physiol. 2018;9:1253.

43. Villamor-Martinez E, Lubach GA, Rahim OM, Degraeuwe P, Zimmermann LJ, Kramer BW, et al. Association of histological and clinical chorioamnionitis with neonatal sepsis among preterm infants: a systematic review, meta-analysis, and meta-regression. Front Immunol. 2020;11:972.

44. Behbodi E, Villamor-Martínez E, Degraeuwe PL, Villamor E. Chorioamnionitis appears not to be a risk factor for patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Sci Rep. 2016;6(1):1-10.

45. Orgeig S, Morrison JL, Daniels CB. Prenatal development of the pulmonary surfactant system and the influence of hypoxia. Respir Physiol Neurobiol. 2011;178(1):129-45.

46. van Westering-Kroon E, Huizing MJ, Villamor-Martínez E, Villamor E. Male disadvantage in oxidative stress-associated complications of prematurity: a systematic review, meta-analysis and meta-regression. Antioxidants. 2021;10(9):1490.

47. Härkin P, Marttila R, Pokka T, Saarela T, Hallman M. Survival analysis of a cohort of extremely preterm infants born in Finland during 2005–2013. J Matern Fetal Neonatal Med. 2021;34(15):2506-12.

48. Kramer BW, Kallapur S, Newnham J, Jobe AH. Prenatal inflammation and lung development. Semin Fetal Neonatal Med. 2009;14(1):2-7.

49. Taglauer E, Abman SH, Keller RL. Recent advances in antenatal factors predisposing to bronchopulmonary dysplasia. Semin Perinatol. 2018;42(7):413-24.

50. Inder TE, Perlman JM, Volpe JJ. Preterm intraventricular hemorrhage/posthemorrhagic hydrocephalus. Volpe's Neurology of the Newborn: Elsevier; 2018. p. 637-98. e21.

51. Gemmell L, Martin L, Murphy K, Modi N, Håkansson S, Reichman B, et al. Hypertensive disorders of pregnancy and outcomes of preterm infants of 24 to 28 weeks' gestation. J Perinatol. 2016;36(12):1067-72.

52. Regev RH, Arnon S, Litmanovitz I, Bauer-Rusek S, Boyko V, Lerner-Geva L, et al. Outcome of singleton preterm small for gestational age infants born to mothers with pregnancy-induced hypertension. A population-based study. J Matern Fetal Neonatal Med. 2015;28(6):666-73.
53. Joseph K. Towards a unified perinatal theory: Reconciling the births-based and fetus-at-risk

models of perinatal mortality. Paediatr Perinat Epidemiol. 2019;33(2):101-12.

54. Joseph K, Kramer MS. The fetuses-at-risk approach: survival analysis from a fetal perspective. Acta Obstet Gynecol Scand. 2018;97(4):454-65.

55. Pierrat V, Ancel PY. Outcomes in extremely low-birthweight infants: What can we learn by comparing epidemiological studies over time? Paediatr Perinat Epidemiol. 2022;36(5):603.

Figure Legends

Fig. 1. Summary of meta-analyses on the association between endotype of prematurity and mortality in infants up to 34 weeks of gestational age.

BW: birth weight; CA: chorioamnionitis; CI: confidence interval; HDP: hypertensive disorders of pregnancy; HELLP: syndrome in pregnancy characterized by hemolysis, elevated liver enzymes and low platelet count; P3: 3rd percentile; P5: 5th percentile; P10: 10th percentile; IUGR: intra-uterine growth restriction defined on the basis of fetal growth assessment

Fig. 2. Summary of meta-analyses on the association between endotype of prematurity and mortality in infants up to 28 weeks of gestational age.

BW: birth weight; CA: chorioamnionitis; CI: confidence interval; HDP: hypertensive disorders of pregnancy; HELLP: syndrome in pregnancy characterized by hemolysis, elevated liver enzymes and low platelet count; P3: 3rd percentile; P5: 5th percentile; P10: 10th percentile

Fig. 3. Meta-regression plot showing the correlation between the effect size of the association endotype-mortality and the mean difference (MD) in gestational age (GA) between exposed and non-exposed groups.

(A) Univariate regression model correlating the difference in GA between chorioamnionitis- exposed and chorioamnionitis-unexposed infants. A total of 53 studies were included (coefficient -0.178; 95% CI -0.298 to -0.068; p = 0.002; R2 analog 0.37). Each week that chorioamnionitis-exposed infants were born earlier than control infants resulted in an increase in mortality log OR of 0.178 (the equivalent of going from an OR of 1.00 to an OR of 1.19).

(B) Univariate regression model correlating the difference in GA between hypertensive disorders of pregnancy (HDP)-exposed and HDP-unexposed infants. A total of 32 studies were included (coefficient -0.249; 95% CI -0.403 to -0.094; p = 0.002; R2 analog 0.17). (C) Univariate regression model correlating the difference in GA between small for GA (SGA)/intrauterine growth restriction (IUGR)-exposed and SGA/IUGR-unexposed infants. A total of 34 studies were included (coefficient - 0.282; 95% CI -0.437 to -0.129; p<0.001; R2 analog 0.38).

Exposure	Meta-analysis	К	Effect	95% CI		Р	Hetero	geneity
			size	Lower limit	Upper limit		l ² (%)	Р
CA	GA (MD in weeks)	52	-0.696	-0.892	-0.499	<0.001	98.4	<0.001
	Male sex (OR)	41	0.969	0.889	1.056	0.474	52.8	<0.001
	HDP (OR)	21	0.110	0.076	0.160	<0.001	81.3	<0.001
	SGA/IUGR (OR)	19	0.351	0.244	0.506	<0.001	80.5	<0.001
HDP	GA (MD in weeks)	28	0.271	0.187	0.355	<0.001	97.9	<0.001
	Male sex (OR)	27	0.778	0.744	0.814	<0.001	47.2	0.004
	CA (OR)	12	0.132	0.080	0.219	<0.001	89.0	<0.001
	SGA/IUGR (OR)	24	4.695	3.572	6.172	<0.001	98.1	<0.001
SGA/IUGR	GA (MD in weeks)	30	0.185	0.023	0.348	0.025	97.3	<0.001
	Male sex (OR)	31	0.950	0.851	1.060	0.355	79.2	<0.001
	CA (OR)	5	0.226	0.140	0.364	<0.001	0.0	0.498
	HDP (OR)	17	4.623	2.620	8.159	<0.001	98.4	<0.001

Table 1. Meta-analyses of other covariates.

CA: chorioamnionitis; CI: confidence interval; GA: gestational age; HDP: hypertensive disorders of pregnancy; IUGR: intra-uterine growth retardation defined on the basis of fetal growth assessment; K: number of studies; MD: mean difference (exposed minus unexposed); OR: odds ratio; SGA: small for gestational age as defined by birth weight percentile.



Figure 1



		Statistics			Hetero	geneity
Number of studies	Odds ratio	Lower limit	Upper limit	p-Value	l² (%)	p-Value
1	2.500	0.743	8.413	0.139	0.0	1.000
5	0.819	0.559	1.200	0.306	74.9	0.003
8	1.274	0.974	1.665	0.077	23.7	0.240
14	1.130	0.911	1.402	0.266	63.5	0.001
3	1.646	0.523	5.175	0.394	82.6	0.003
4	0.682	0.392	1.186	0.175	48.8	0.118
3	1.233	0.963	1.578	0.097	0.0	0.581
10	1.134	0.909	1.415	0.266	68.1	0.001
11	2.400	1.650	3.493	<0.001	86.0	<0.001
1	2.380	1.158	4.893	0.018	0.0	1.000
3	1.501	0.427	5.278	0.527	89.7	<0.001
15	2.324	1.685	3.206	<0.001	85.4	<0.001

Figure 2



В

Α

С

Supplementary Online Content

Tamara M Hundscheid, Eduardo Villamor-Martinez, Eduardo Villamor. Association between Endotype of Prematurity and Mortality: A Systematic Review, Metaanalysis and Meta-regression

1. Methods

1.1 Search strategy.

1.2 Supplementary information on methods.

2. **Results**

eFigure 1. PRISMA Diagram of the Systematic Search.

eFigure 2. Meta-analysis on association between chorioamnionitis and mortality in infants with gestational age up to 34 weeks.

eFigure 3. Meta-analysis on association between chorioamnionitis and mortality in infants with gestational age up to 28 weeks.

eFigure 4. Meta-analysis on association between hypertensive disorders of pregnancy and mortality in infants with gestational age up to 34 weeks

eFigure 5. Meta-analysis on association between hypertensive disorders of pregnancy and mortality in infants with gestational age up to 28 weeks.

eFigure 6. Meta-analysis on association between small for gestational age/intrauterine growth restriction and mortality in infants with gestational age up to 34 weeks.

eFigure 7. Meta-analysis on small for gestational age/intrauterine growth restriction and mortality in infants with gestational age up to 28 weeks

eFigure 8. Funnel plot for publication bias analysis for the studies included in meta-analysis.

eTable 1. Characteristics of included studies and Newcastle-Ottawa Scale.

eTable 2. Subgroup analysis based on characteristics of the studies.

eTable 3. Meta-regression on continuous variables.

eTable 4. Subgroup analysis on gestational age.

eTable 5. Subgroup analysis for continent.

eTable 6. Meta- analysis on antenatal corticosteroids.

1. Methods 1.1. Search strategy

PubMed

((Chorioamnionitis[Mesh] OR chorioamnionitis [TIAB] OR CA [TIAB] OR amnionitis [TIAB] OR funisitis [TIAB] OR fetal membranes, premature rupture [Mesh] OR placenta diseases [Mesh] OR placenta disease [TIAB] OR PPROM[TIAB] OR preterm premature rupture of membrane*[TIAB])

AND (mortality[Mesh] OR mortality, premature [Mesh] OR perinatal mortality [Mesh] OR infant mortality [Mesh] OR mortality[TIAB] OR death[TIAB] mortality[Mesh] OR-mortality, premature [Mesh] OR perinatal mortality [Mesh] OR infant mortality [Mesh] OR mortality [TIAB] OR death [TIAB] OR short-term complication [TIAB] short term complication [TIAB] OR complication [TIAB])

AND (infant* [TIAB] OR Infants, Newborn[Mesh] OR Newborn* [TIAB] OR Neonate* [TIAB] OR neonatal[TIAB] OR Decreased gestational age [TIAB] OR premature gestation [TIAB] OR prematurity [TIAB] OR preterm [TIAB] OR premature [TIAB]))

<u>OR</u>

((Placental insufficiency [Mesh] OR placental insufficiency [TIAB] OR placental dysfunction [TIAB] OR Hypertension, pregnancy- induced [TIAB] OR pregnancy induced hypertension[TIAB] OR gestational hypertension[TIAB] OR pregnancy transient hypertension [TIAB] OR GHD [TIAB] OR pre-eclampsia [Mesh] OR pre-eclampsia [TIAB] OR preeclampsia [TIAB] OR HELLP syndrome [Mesh] OR HELLP syndrome [TIAB])

AND (mortality[Mesh] OR mortality, premature [Mesh] OR perinatal mortality [Mesh] OR infant mortality [Mesh] OR mortality[TIAB] OR death[TIAB] mortality[Mesh] OR-mortality, premature [Mesh] OR perinatal mortality [Mesh] OR infant mortality [Mesh] OR mortality [TIAB] OR death [TIAB] OR short-term complication [TIAB] short term complication [TIAB] OR complication [TIAB])

AND (infant* [TIAB] OR Infants, Newborn[Mesh] OR Newborn*[TIAB] OR Neonate*[TIAB] OR neonatal[TIAB] OR Decreased gestational age [TIAB] OR premature gestation [TIAB] OR prematurity [TIAB] OR preterm [TIAB] OR premature [TIAB]))

OR

((Fetal growth restriction [Mesh] OR fetal growth restriction [TIAB] OR IUGR OR intrauterine growth restriction[TIAB] OR intrauterine growth restriction [TIAB] OR infant, small for gestational age [TIAB] OR SGA OR small for gestational age [TIAB])

AND (mortality[Mesh] OR mortality, premature [Mesh] OR perinatal mortality [Mesh] OR infant mortality [Mesh] OR mortality[TIAB] OR death[TIAB] mortality[Mesh] OR-mortality, premature [Mesh] OR perinatal mortality [Mesh] OR infant mortality [Mesh] OR mortality [TIAB] OR death [TIAB] OR short-term complication [TIAB] short term complication [TIAB] OR complication [TIAB])

AND (infant* [TIAB] OR Infants, Newborn[Mesh] OR Newborn*[TIAB] OR Neonate*[TIAB] OR neonatal[TIAB] OR Decreased gestational age [TIAB] OR premature gestation [TIAB] OR prematurity [TIAB] OR preterm [TIAB] OR premature [TIAB]))

Embase

((exp chorioamnionitis/ OR chorioamnionitis.ti,ab. OR CA.ti,ab. OR amnionitis.ti,ab. OR funisitis.ti,ab. OR exp premature fetus membrane rupture/ OR exp placenta disorder/ OR placenta disease.ti,ab. OR PPROM.ti,ab. OR preterm premature rupture of membrane.ti,ab.) AND (exp mortality/ OR mortality.ti,ab. OR exp premature mortality/ OR premature mortality.ti,ab. OR exp perinatal mortality/ OR perinatal mortality.ti,ab. OR exp newborn mortality/ OR newborn mortality.ti,ab. OR exp infant mortality/ OR infant mortality.ti,ab. OR mortality.ti,ab. OR death.ti,ab. AND exp complication/ OR complication.ti,ab. OR shortterm complication.ti,ab. OR short term complication.ti,ab.) AND (exp prematurity/ OR infant.ti,ab. OR preterm infant.ti,ab. OR newborn.ti,ab. OR neonate.ti,ab. OR neonatal.ti,ab. OR decreased gestational age.ti,ab. OR premature gestation.ti,ab. OR prematurity.ti,ab. OR preterm.ti,ab. OR premature.ti,ab.))

OR

((exp placental insufficiency/ OR placental insufficiency.ti,ab. OR placental dysfunction.ti,ab. OR exp maternal hypertension/ OR pregnancy induced hypertension.ti,ab. OR gestational hypertension.ti,ab. OR pregnancy transient hypertension.ti,ab. OR GHD.ti,ab. OR pre-eclampsia OR HELLP) AND (exp mortality/ OR mortality.ti,ab. OR exp premature mortality/ OR premature mortality.ti,ab. OR exp perinatal mortality/ OR perinatal mortality.ti,ab. OR exp newborn mortality/ OR newborn mortality.ti,ab. OR exp infant mortality/ OR infant mortality.ti,ab. OR mortality.ti,ab. OR death.ti,ab. AND exp complication/ OR complication.ti,ab. OR short-term complication.ti,ab. OR short term complication.ti,ab.) AND (exp prematurity/ OR infant.ti,ab. OR preterm infant.ti,ab. OR newborn.ti,ab. OR neonate.ti,ab. OR neonatal.ti,ab. OR decreased gestational age.ti,ab. OR premature gestation.ti,ab. OR prematurity.ti,ab. OR preterm.ti,ab. OR premature.ti,ab.))

<u>OR</u>

((exp intrauterine growth restriction/ OR fetal growth restriction.ti,ab. OR fetal growth restriction.ti,ab. OR IUGR.ti,ab. OR intrauterine growth restriction.ti,ab. OR intrauterine growth restriction.ti,ab. OR SGA.ti,ab. OR small for gestational age.ti,ab.) AND (exp mortality/ OR mortality.ti,ab. OR exp premature mortality/ OR premature mortality.ti,ab. OR exp perinatal mortality/ OR perinatal mortality.ti,ab. OR exp newborn mortality/ OR newborn mortality.ti,ab. OR exp infant mortality/ OR infant mortality.ti,ab. OR mortality.ti,ab. OR death.ti,ab. AND exp complication/ OR complication.ti,ab. OR short-term complication.ti,ab. OR short term complication.ti,ab.) AND (exp prematurity/ OR infant.ti,ab. OR preterm infant.ti,ab. OR newborn.ti,ab. OR neonate.ti,ab. OR neonatal.ti,ab. OR decreased gestational age.ti,ab. OR premature gestation.ti,ab. OR prematurity.ti,ab. OR preterm.ti,ab. OR premature.ti,ab.))

No language limits were set. Narrative reviews, systematic reviews, case reports, letters, editorials, and commentaries were excluded, but read to identify potential additional studies. Additional strategies to identify studies included manual review of reference lists from key articles that fulfilled our eligibility criteria, use of "related articles" feature in PubMed, and use of the "cited by" tool in Web of Science and Google scholar. Two reviewers independently screened the results of the searches, and included studies according to the inclusion criteria using EndNote (RRID:SCR_014001), using the methodology described by Bramer et al. (1)

1.2. Supplementary information on methods

Study selection

Studies were included if they examined preterm (GA <34 weeks) and/or very low birth weight (<1500g) infants and reported data that could be used to measure the association between exposure to chorioamnionitis, hypertensive disorders of pregnancy (HDP) or small for gestational age (SGA)/intrauterine growth restriction (IUGR) and mortality before hospital discharge. Therefore, we selected observational studies in which the exposure (chorioamnionitis, HDP or SGA/IUGR) was the independent variable and the outcome (mortality before hospital discharge) the dependent variable as well as studies in which the outcome was the independent variable and the exposure the dependent variable. Studies that exclusively included late preterm infants (GA \geq 34 weeks) or that combined preterm and term infants were excluded. Due to the high number of included studies, no

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

additional efforts were made to clarify definitions or other data with the authors. Abstracts and unpublished studies were also excluded. To identify relevant studies, two reviewers (TH, EV-M) independently screened the results of the searches and applied inclusion criteria using a structured form. Discrepancies were resolved through discussion or consultation with a third reviewer (EV).

Data extraction and quality assessment

Data extracted from each study included citation information, language of publication, country of conducted research, time period of the study, study objectives, study design, inclusion/exclusion criteria, definition criteria for chorioamnionitis, HDP, IUGR, SGA and mortality, patient characteristics, and results (including raw numbers or summary statistics when raw numbers were not available). A study was categorized as a case-control when each case was matched with a control in a predetermined ratio (1:1, 1:2, 1:3, etc.). A study was considered a cohort study when it included, prospectively or retrospectively, a group of infants during a given period, regardless of the number of infants included. Therefore, small cohorts were also included.

Any definition of chorioamnionitis, HDP, IUGR, or SGA was accepted but we performed sub-group analysis based on the different definitions. When a study used more than one definition criteria for growth restriction, definitions based on assessment of fetal growth (i.e., IUGR) prevailed over definitions based on BW. When a study used different BW threshold percentiles to define SGA, data from the lowest percentile were included. When a study did not specify the threshold percentile used, it was grouped together with the studies that used the 10th percentile.

Methodological quality was assessed using the Newcastle-Ottawa Scale for cohort or case-control studies.(2) This scale uses a star rating system (range: 0-9 stars) scoring three aspects of the study: selection (0-4), comparability (0-2) and exposure/outcome (0-3). Two reviewers (TH, EV-M) independently assessed the methodological quality of each study. Discrepancies were resolved through discussion.

Statistical analysis

Studies were combined and analyzed using COMPREHENSIVE META-ANALYSIS V3.0 software (Biostat Inc., Englewood, NJ, USA). For dichotomous outcomes, the odds ratio (OR) with 95% confidence interval (CI) was calculated from the data provided in the studies. Reported ORs were included when studies reported them and did not include the numerical data for the calculation of the OR. For continuous outcomes, the mean difference with 95% CI was calculated. When studies reported continuous variables as median and range or interquartile range, we estimated the mean and standard deviation using the method of Wan et al. and the calculator they provided. (3)

Due to anticipated heterogeneity, summary statistics were calculated with a random-effects model. This model accounts for variability between studies as well as within studies. Subgroup analyses were conducted according to the mixed-effects model.(4) In this model, a random-effects model is used to combine studies within each subgroup, and a fixed-effect model is used to combine subgroups and yield the overall effect. The study-to-study variance (tau-squared) is not assumed to be the same for all subgroups. This value is computed within subgroups and not pooled across subgroups. Statistical heterogeneity was assessed by Cochran's Q statistic and by the I^2 statistic, which is derived from Q and describes the proportion of total variation that is due to heterogeneity beyond chance.(5) The I² statistic was interpreted as follows: low heterogeneity ($25\% \le I^2 < 50\%$), moderate heterogeneity ($50\% \le I^2 < 75\%$), and high heterogeneity ($I^2 \ge 75\%$). We used the Egger's regression test and funnel plots to assess publication bias. A probability value of less than 0.05 (0.10 for heterogeneity) was considered statistically significant.

Potential sources of heterogeneity were assessed through subgroup analysis and/or random effects (method of moments) univariate meta-regression analysis.⁵ For continuous covariates (examples: difference in mean gestational age between infants exposed and unexposed to chorioamnionitis) we used meta-regression analyses to test whether there was a significant relationship between the covariate and effect size, as indicated by a Z-value and an associated p-value. Meta-regression coefficient indicates the change in the log of the OR of the association between mortality and the corresponding exposure for a unit change in the predictor covariate. Subgroups were compared using meta-regression for categorical covariates. For both categorical and continuous covariates, the R² analog, defined as the total between-study variance explained by the moderator, was calculated based on the meta-regression matrix.(6) Covariates defined a priori were: 1) Continuous: study time (median year of cohort inclusion), differences between exposed and unexposed infants on GA; 2) Categorical: chorioamnionitis type, HDP type, SGA/IUGR type, mean difference of GA between exposed and unexposed

infants statistically significant (P<0.05, yes/no), geographical location (continent) of the study, prospective vs retrospective and cohort vs case-control study. The clinical covariates were selected based on their relevance on the outcome of mortality.

2. Results



eFigure 1. PRISMA Diagram of the Systematic Search.



eFigure 2. Meta-analysis on association between chorioamnionitis and mortality in infants with gestational age up to 34 weeks. CA: chorioamnionitis, CI: confidence interval.



eFigure 3. Meta-analysis on association between chorioamnionitis and mortality in infants with gestational age up to 28 weeks. CA: chorioamnionitis, CI: confidence interval

Subgroup	Study name	Odds ratio and 95% Cl	<u>s</u>	tatistics	for each s	tudy
			Odds ratio	Lower limit	Upper limit	p-Value
	Torchin 2016	_ i	0.320	0.206	0.496	0.000
	Shankaran 2002		0.389	0.328	0.461	0.000
	Gagliardi 2013		0.437	0.300	0.635	0.000
	Gagliardi 2014		0.440	0.369	0.524	0.000
	McBride 2015		0.598	0.572	0.624	0.000
	Chen 2006		0.604	0.569	0.642	0.000
	Chard 2001		0.616	0.504	0.752	0.000
	Bolisetty 2015		0.648	0.472	0.890	0.007
	Regev 2015		0.707	0.562	0.889	0.003
Any HDP	- Matic 2017		0.712	0.534	0.948	0.020
	Ushida 2020		0.728	0.608	0.872	0.001
	Shin 2020		0.813	0.549	1.203	0.300
	Torrance 2007		0.819	0.317	2.11/	0.681
	Klibride 1990		0.929	0.325	2.654	0.890
	Park 2012		1.008	0.403	2.522	0.980
	Rocha 2018 Razak 2018		2.097	0.555	6 204	0.766
	Holtrop 1994		4 030	1 309	12 /01	0.101
	Overall		0.605	0 543	0.674	0.010
			0.005	0.545	0.074	0.000
	Locatelli 2004		0.394	0.136	1.142	0.086
	Sabino 2017		0.444	0.157	1.257	0.126
	Bacak 2004		0.501	0.365	0.687	0.000
	Jelin 2010		0.565	0.368	0.867	0.009
	Gray 1997		0.603	0.170	2.140	0.434
	Procianoy 2010		0.724	0.523	1.003	0.052
	Gemmell 2016		0.817	0.699	0.956	0.012
	Hentges 2015		0.848	0.294	2.447	0.761
Descalaracia	Wilmink 2019		0.924	0.395	2.157	0.854
Preeclampsia	- Friedman 1995		1.000	0.408	2.452	1.000
	Chang 2004		1.029	0.255	4.150	0.909
	Turupop 2011		1.100	0.234	4./3/	0.050
	Serenius 2004		1 350	0.055	3 030	0.913
	Hiett 2001		1.460	0.620	3.442	0.387
	De Souza Rugolo 2015		1.556	0.241	10.049	0.643
	Naveri 2018		1.619	0.771	3.398	0.203
	Costeloe 2000		1.630	0.710	3,742	0.249
	Overall		0.792	0.657	0.956	0.015
	[D-14- 1005		0.500	0.204	0.050	0.026
	Palta 1996		0.522	0.284	1.624	0.036
	Soliman 2017		0.578	0.205	2.270	0.298
Dropolomocio LICU D	Rilli 1990		0.075	0.154	0.005	0.051
Preeciampsia-HELLP	Abramovici 1999		0.054	0.345	1 2 2 2	0.005
	Aslan 2004		1.444	0.365	5.721	0.601
	Overall		0.683	0.557	0.837	0.001
0	L					
Overall			0.654	0.600	0.712	0.000
		0.01 0.1 1 10 100				
		$\longleftarrow \longrightarrow$				
		Lower Higher				
		mortality risk mortality risk				

eFigure 4. Meta-analysis on association between hypertensive disorders of pregnancy and mortality in infants with gestational age up to 34 weeks. HDP: hypertensive disorders of pregnancy, HELLP: syndrome in pregnancy characterized by hemolysis, elevated liver enzymes and low platelet count, CI: confidence interval.



eFigure 5 Meta-analysis on association between hypertensive disorders of pregnancy and mortality in infants with gestational age up to 28 weeks HDP: hypertensive disorders of pregnancy, HELLP: syndrome in pregnancy characterized by hemolysis, elevated liver enzymes and low platelet count, CI: confidence interval.

Subgroup	Study name	Odds ratio and 95% Cl		Statistics f	or each stu	ıdy
			Odds	Lower	Upper	p-Value
	Thompson 1993		0.144	0.080	0.262	0.000
	Lucey 2004		0.219	0.177	0.271	0.000
	Upadhyay 2015		0.249	0.100	0.619	0.003
	Tagare 2013		0.283	0.115	0.692	0.006
	Locatelli 2005		0.622	0.222	1.746	0.367
	Claas 2010		0.778	0.363	1.667	0.518
	Bacak 2004		0.861	0.608	1.220	0.400
	Tannirwar 2016		1.097	0.554	2.172	0.791
	Piper 1996		1.131	0.902	1.419	0.287
	Ley 1997		1.327	0.869	2.024	0.190
	Bernstein 2000		1.410	1.200	1.657	0.000
	Ferdynus 2009		1.501	0.500	4.504	0.469
	Woo Lim 2015		1.592	1.138	2.227	0.007
	Melamed 2016	i⊕	1.644	1 262	2 1/1	0.240
	Wadhawan 2007		1,700	1.202	1 966	0.000
	Sharma 2004		1.805	0.984	3,311	0.056
	Lal 2003		2.044	1.521	2,746	0.000
BW <p10< td=""><td>Tsai 2015</td><td></td><td>2.091</td><td>1.591</td><td>2.749</td><td>0.000</td></p10<>	Tsai 2015		2.091	1.591	2.749	0.000
	De Jesus 2013		2.200	1.772	2.732	0.000
	Garite 2004		2.211	1.904	2.567	0.000
	Zaw 2003		2.380	1.158	4.893	0.018
	Giapros 2012		2.444	1.197	4.994	0.014
	Reiss 2003		2.453	1.660	3.624	0.000
	Doyle 2001		2.575	1.179	5.623	0.018
	Grill 2014		2.586	1.732	3.861	0.000
	Tokumasu 2016		2.724	2.211	3.357	0.000
	Wirbelauer 2010		2.900	0.436	19.286	0.271
	Kent 2012		2.908	2.031	4.164	0.000
	Jensen 2019		3.012	2.394	3.788	0.000
	Baer 2016		3.453	2.650	4.500	0.000
	Malhotra 2015		4.074	2.051	8.093	0.000
	Ausbeck 2021		5.412	2.102	13.931	0.000
	Wocadio 1994		5.952	3.236	10.946	0.000
	Rakza 2007		0.429	0.013	07.434 72.767	0.121
	Gorther 1999		14.491	2.840	/3./0/	0.001
	Overall	Ť Ť	1.029	1.270	2.090	0.000
	Aucott 2004		1.671	0.599	4.660	0.327
	Westby Wold 2009		1.971	0.885	4.387	0.097
BW <p5< td=""><td>Ray 2017</td><td></td><td>2.786</td><td>2.362</td><td>3.286</td><td>0.000</td></p5<>	Ray 2017		2.786	2.362	3.286	0.000
	Overall		2.714	2.313	3.184	0.000
	-					
	Bolisetty 2015	- ● i	0.648	0.472	0.890	0.007
	Yu 2011		1.027	0.601	1.754	0.924
	Lee 2001		1.125	0.392	3.231	0.827
	Amin 1997		1.163	0.679	1.993	0.581
B/W/ <d2< td=""><td>Bardin 1997</td><td></td><td>1.553</td><td>0.749</td><td>3.221</td><td>0.237</td></d2<>	Bardin 1997		1.553	0.749	3.221	0.237
DWVPS	Serenius 2004		2.380	1.190	4.760	0.014
	Shah 2012		2.556	1.994	3.276	0.000
	Grisaru-Granovsky 2012		2.647	2.225	3.150	0.000
	Soudée 2014		9.500	2.928	30.819	0.000
	Overall		1.704	1.088	2.667	0.020
	Г					
	Candel Pau 2016		0.411	0.042	4.058	0.446
	Sadeghi Moghaddam 2015		0.610	0.348	1.069	0.084
	Broaszski 2009		0.700	0.239	2.048	0.515
	Regliardi 2012		1.022	0.673	1.154	0.358
ILICD -	Gagilardi 2013		1.032	0.082	1.502	0.654
IUGK	El Avoubi 2016		1.302	1 1 70	4.114	0.004
	Fernandez-Rodriguez 2010		2 150	1.1/2	13 796	0.000
	Nobile 2017		3,016	1,797	5,091	0.000
	Hartung 2005		8.125	0.956	69.205	0.055
	Overall		1 204	0.848	1 708	0.000
	Corcian		11201	01010	1.700	0.255
Overall			2.112	1.871	2.383	0.000
		0.01 0.1 1 10 100				
		$\longleftarrow \longrightarrow$				
		lower Higher				
		mortality risk mortality risk				
		,,,,				

eFigure 6. Meta-analysis on association between small for gestational age/intrauterine growth restriction and mortality in infants with gestational age up to 34 weeks. BW: birth weight, P10: 10th percentile, P5: 5th percentile, P3: 3rd percentile; IUGR: intrauterine growth restriction defined on the basis of fetal growth assessment, CI: confidence interval.



eFigure 7. Meta-analysis on association between small for gestational age/intrauterine growth restriction and mortality in infants with gestational age up to 28 weeks. BW: birth weight, P10: 10th percentile, P5: 5th percentile, P3: 3rd percentile, CI: confidence interval.



eFigure 8. Funnel plot for publication bias analysis for the studies included in meta-analysis

- A. Meta-analysis of chorioamnionitis and mortality
- B. Meta-analysis of hypertensive disorders of pregnancy (HDP) and mortality
- C. Meta-analysis of small for gestational age (SGA)/intrauterine growth restriction (IUGR) and mortality

Table 1. Characteristics of the included studies and Newcastle-Ottawa Scale

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Abramovici, 1999(7)	USA	cohort	no	1279	1	N	HDP	HDP: HELLP	4	0	3	7
Ahn, 2012(8)	South Korea	cohort	yes	257	1	30.6	CA	CA: Histologic	4	1	3	8
Alexander, 1998(9)	USA	cohort	yes	1367	1	28.9	CA	CA: Clinical	4	2	3	9
Alfiero Bordigato, 2011(10)	Italy	cohort	yes	29	1	26.7	CA	CA: Histologic	4	1	3	8
Amin, 1997(11)	Canada	ca-co	no	503	1	28.3	SGA	SGA: BW <p3< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p3<>	4	0	3	7
Arayici, 2014(12)	Turkey	cohort	no	281	1	28.9	CA	CA: Histologic	4	1	3	8
Aslan, 2004(13)	Turkey	cohort	no	110	1	32.3	HDP	HDP: HELLP	4	1	3	8
Aucott, 2004(14)	USA	ca-co	no	113	1	28.9	SGA	SGA: BW <p5< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p5<>	4	2	3	9
Ausbeck, 2021(15)	International	cohort	no	180	9	25.8	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Bacak, 2004(16)	USA	ca-co	no	1742	Network	25.4	Mortality	HDP: PE SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Baer, 2016(17)	USA	cohort	no	8640	Network	33.6	SGA	SGA: BW <p10< td=""><td>4</td><td>1</td><td>3</td><td>8</td></p10<>	4	1	3	8
Bardin, 1997 (18)	Canada	cohort	yes	184	1	25.4	SGA	SGA: BW <p3< td=""><td>4</td><td>1</td><td>3</td><td>8</td></p3<>	4	1	3	8
Baud, 2000(19)	France	cohort	yes	685	1	29.8	CA	CA: Clinical	4	1	3	8
Been, 2009(20)	Netherlands	cohort	yes	301	1	30.7	CA	CA: Histologic	4	2	3	9
Bernstein, 2000(21)	USA	cohort	no	19759	212	Ν	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Bolisetty, 2015(22)	Australia	cohort	yes	4454	10	28.6	Mortality	CA: Any CA HDP: Any HDP SGA: BW <p3< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p3<>	4	0	3	7
Bossung, 2020(23)	Germany	cohort	no	16035	62	28.2	HDP	HDP: HELLP	4	2	3	9
Botet, 2011(24)	Spain	ca-co	yes	328	1	28.3	CA	CA: Clinical	4	1	3	8
Brodszki, 2009(25)	Sweden	Ca-co	no	417	1	27.1	SGA	SGA: IUGR	4	1	3	8
Bry, 2015(26)	Sweden	cohort	yes	24	1	25.9	CA	CA: Histologic	4	0	3	7
Candel Pau, 2016(27)	Spain	cohort	yes	129	1	29.6	SGA	SGA: BW <p3< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p3<>	4	0	3	7
Chard, 2001(28)	UK	cohort	no	6946	Network	28.7	HDP	HDP: Any HDP	4	0	3	7
Chen, 2006(29)	USA	cohort	no	237000	Network	28.7	HDP	HDP: Any HDP	4	2	3	9
Cheng, 2004(30)	Taiwan	ca-co	no	89	1	29.0	HDP	HDP: PE	4	2	3	9
Claas, 2010(31)	The Netherlands	cohort	no	146	1	30.0	SGA	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Costeloe, 2000(32)	UK and Ireland	cohort	yes	811	276	24.1	Mortality	CA: Clinical HDP: PE	4	2	3	9
De Felice, 2005(33)	Italy	ca-co	yes	116	1	28.1	CA	CA; Histologic	4	2	3	9
De Jesus, 2013(34)	USA	cohort	no	2971	17	25.0	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
De Souza Rugolo, 2015(35)	Brazil	ca-co	yes	60	1	Ν	HDP	HDP: PE	4	0	3	7
Dempsey, 2005(36)	Canada	cohort	yes	330	1	27.0	CA	CA: Histologic	4	1	3	8
Dexter, 2000(37)	USA	cohort	yes	287	1	26.4	CA	CA: Histologic	4	2	2	8
Doyle, 2001(38)	Australia	cohort	no	335	6	25.3	Mortality	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Ecevit, 2014(39)	Turkey	cohort	no	19	1	25.5	CA	CA: Histologic	4	2	3	9
El Ayoubi, 2016(40)	International (Europe)	cohort	yes	4585	10	28.6	SGA	SGA: IUGR	4	2	3	9
El-Metwally, 2000(41)	USA	cohort	no	211	1	23.7	Mortality	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Erdemir, 2013(42)	Turkey	cohort	yes	57	1	30.8	Mortality	CA: Histologic	4	2	3	9
Ferdynus, 2009(43)	France	cohort	yes	572	18	30.5	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Fernandez-Rodriguez, 2021(44)	Spain	cohort	no	94	1	31.4	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Friedman, 1995(45)	USA	cohort	no	446	1	31.9	HDP	HDP: PE	4	2	3	9
Fukami, 2007(46)	Japan	cohort	yes	121	1	26.0	Mortality	CA: Clinical	4	2	3	9
Fung, 2003(47)	Hong Kong	cohort	no	72	1	26.2	CA	CA: Any CA	4	0	3	7
Gagliardi, 2013(48)	Italy	cohort	no	2085	51	27.3	CA HDP SGA	CA: Clinical HDP: Any HDP SGA: IUGR	4	2	3	9
Gagliardi, 2014(49)	Italy	cohort	yes	3606	82	28.2	CA HDP	CA: Clinical HDP: Any HDP	4	2	3	9
García-Muñoz, 2014 (50)	Spain	cohort	no	8330	1	28.5	CA	CA: Clinical	4	2	3	9
Garite, 2004(51)	USA	cohort	no	25734	124	31.0	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Gemmell, 2016(52)	International	cohort	no	12477	6 networks	N	HDP	HDP: PE	4	2	3	9
Giapros, 2012(53)	Greece	cohort	no	210	1	28.5	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
González-Luis, 2002(54)	Spain	ca-co	yes	135	1	28.9	CA	CA: Clinical	4	0	3	7
Gortner, 1999(55)	Germany	cohort	yes	317	6	29.6	SGA	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Gray, 1997(56)	Australia	cohort	yes	190	1	27.0	CA HDP	CA: Any CA HDP: PE	4	0	3	7
Grill, 2014(57)	Austria	cohort	no	1117	1	26.7	Mortality	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Grisaru-Granovsky, 2012(58)	Israel	cohort	yes	9756	28	28.2	SGA	SGA: BW <p3< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p3<>	4	2	3	9
Hartung, 2005(59)	Germany	ca-co	no	88	1	N	SGA	SGA: IUGR	4	2	3	9
Hendson, 2011(60)	Canada	cohort	yes	628	1	26.9	CA	CA: Histologic	4	1	3	8
Hentges, 2015(61)	Brazil	cohort	yes	88	1	30.0	HDP	HDP: PE	4	2	3	9
Hiett, 2001(62)	USA	ca-co	no	116	2	27.1	HDP	HDP: PE	4	2	3	9
Holcroft, 2004(63)	USA	cohort	no	354	1	30.1	CA	CA: Histologic	4	2	3	9
Holtrop, 1994(64)	USA	cohort	no	82	1	24.0	Mortality	HDP: Any HDP	4	2	3	9
Hong, 2021(65)	South Korea	cohort	no	474	1	32.8	CA	CA: Histologic	4	2	3	9
Jelin, 2010(66)	USA	cohort	no	1709	1	Ν	HDP	HDP: PE	4	2	2	8
Jensen, 2019(67)	USA	cohort	no	6708	Network	28.7	SGA	SGA: BW <p10< td=""><td>4</td><td>1</td><td>3</td><td>8</td></p10<>	4	1	3	8
Kent, 2005(68)	Australia	cohort	yes	220	1	27.7	CA	CA: Histologic	4	2	3	9
Kent, 2012(69)	Australia	cohort	no	2701	10	26.3	Mortality	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Kilbride, 1990(70)	USA	cohort	yes	124	1	25.5	Mortality	CA: Any CA HDP: Any HDP	4	2	3	9
Kim, 1996(71)	USA	cohort	no	106	1	28.0	HDP	HDP: HELLP	4	1	3	8
Kim, 2015(72)	South Korea	cohort	no	258	1	29.0	Mortality	CA: Histologic	4	2	3	9

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Lal, 2003(73)	UK	cohort	no	2834	16	28.7	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Lee, 2001(74)	USA	cohort	no	110	1	30.0	SGA	SGA: BW <p3< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p3<>	4	2	3	9
Lee, 2006(75)	Hong Kong	cohort	no	105	1	28.7	CA	CA: Histologic	4	2	3	9
Lee, 2015(76)	South Korea	cohort	no	339	1	31.8	CA	CA: Histologic	4	2	3	9
Lee, 2019(77)	South Korea	cohort	yes	2900	60	28.4	CA	CA: Histologic	4	2	3	9
Ley, 1997(78)	Sweden	cohort	yes	830	1	N	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Liu, 2014(79)	China	cohort	yes	216	1	29.7	CA	CA: Histologic	4	2	3	9
Liu, 2021(80)	Taiwan	cohort	no	129	1	27.1	CA	CA: Histologic	4	2	3	9
Locatelli, 2005(81)	Italy	cohort	no	59	1	26.4	Mortality	CA: Clinical HDP: PE SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Lucey, 2004(82)	International	cohort	yes	1943	346	23.3	Mortality	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Madoglio, 2016(83)	Brazil	cohort	yes	73	1	28.7	HDP	HDP: PE	4	2	3	9
Maisonneuve, 2020(84)	France	Cohort	yes	1470	447	27.7	CA	CA: Histologic	4	2	3	9
Malhotra, 2015(85)	Australia	cohort	yes	459	1	28.2	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Markestad, 2005(86)	Norway	cohort	yes	459	14	27.2	Mortality	CA: Clinical	4	2	3	9
Matić, 2017(87)	Australia	cohort	no	2549	10	26.1	HDP	HDP: Any HDP	4	2	3	9
McBride, 2015(88)	USA	cohort	no	88275	667	28.5	HDP	HDP: Any HDP	4	2	3	9
Melamed, 2016(89)	Canada	cohort	no	6567	24	29.7	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Monier, 2017(90)	France	cohort	no	2919	447	27.7	SGA	SGA: IUGR	4	2	3	9
Mu, 2008(91)	Taiwan	cohort	yes	119	1	28.6	CA	CA: Histologic	4	2	2	8
Nasef, 2013(92)	Turkey	cohort	no	274	1	27.1	CA	CA: Histologic	4	1	3	8
Natarajan, 2008(93)	USA	cohort	yes	48	1	27.3	CA	CA: Histologic	4	1	3	8
Nayeri, 2018(94)	USA	cohort	yes	378	1	29.2	CA HDP	CA: Clinical HDP: PE	4	2	3	9
Nicaise, 2002(95)	France	cohort	yes	118	1	29.8	CA	CA: Histologic	4	2	3	9
Nobile, 2017(96)	Italy	cohort	no	515	1	28.8	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Ogunyemi, 2003(97)	USA	cohort	no	774	1	29.4	CA	CA: Histologic	4	1	3	8
Oh, 2015(98)	South Korea	cohort	no	91	1	27.1	CA	CA: Histologic	4	1	3	8
Palta, 1996(99)	USA	cohort	no	749	7	29.2	HDP	HDP: HELLP	4	2	3	9
Pappas, 2014(100)	USA	cohort	no	2390	16	24.3	CA	CA: Histologic	4	1	3	8
Park, 2012(101)	South Korea	cohort	no	191	1	29.2	HDP	HDP: Any HDP	4	2	3	9
Park, 2017(102)	South Korea	cohort	no	138	1	31.0	CA	CA: Histologic	4	2	3	9
Pietrasanta, 2019(103)	Italy	cohort	yes	807	1	31.8	CA	CA: Histologic	4	2	3	9
Piper, 1996(104)	USA	cohort	no	4183	1	30.7	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Plakkal, 2013(105)	Canada	cohort	no	449	1	26.0	CA	CA: Histologic	4	2	3	9
Procianoy, 2010(106)	Brazil	cohort	yes	911	6	30.2	HDP	HDP: PE	4	2	3	9
Puri, 2016(107)	USA	cohort	no	106	3	27.1	CA	CA: Histologic	4	2	3	9

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Rakza, 2007(108)	France	cohort	yes	48	1	28.0	SGA	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Ray, 2017(109)	Canada	cohort	yes	13426	1	28.8	SGA	SGA: BW <p5< td=""><td>4</td><td>1</td><td>3</td><td>8</td></p5<>	4	1	3	8
Razak, 2020(110)	Canada	ca-co	no	237	1	29.2	HDP	HDP: Any HDP	4	2	3	9
Regev, 2015(111)	Israel	cohort	yes	2139	28	29.9	HDP	HDP: Any HDP	4	2	3	9
Reiss, 2003(112)	Germany	cohort	no	1365	1	30.0	SGA	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Richardson, 2006(113)	Canada	cohort	yes	660	1	30.1	CA	CA: Histologic	4	1	3	8
Rocha, 2006(114)	Portugal	cohort	no	452	3	30.7	CA	CA: Histologic	4	1	3	8
Rocha, 2018(115)	Portugal	cohort	yes	494	11	27.2	HDP	HDP: Any HDP	4	1	3	8
Rodríguez-Trujillo, 2016(116)	Spain	cohort	yes	165	1	31.2	CA	CA: Clinical	4	2	3	9
Ryan, 2019(117)	Ireland	cohort	no	499	1	27.3	CA	CA: Histological	4	1	3	8
Sabino, 2017(118)	Italy	ca-co	no	93	1	30.2	HDP	HDP: PE	4	0	3	7
Sadeghi Moghaddam, 2015(119)	Iran	cohort	no	437	1	NA	Mortality	SGA: IUGR	4	0	3	7
Salas, 2013(120)	USA	cohort	no	343	1	25.9	CA	CA: Histologic	4	2	3	9
Serenius, 2004(121)	Sweden	cohort	no	224	2	24.2	Mortality	CA: Clinical HDP: PE SGA: BW <p3< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p3<>	4	2	3	9
Shah, 2012(122)	Canada	cohort	no	17148	24	29.6	SGA	SGA: BW <p3< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p3<>	4	0	3	7
Shankaran, 2002(123)	USA	cohort	yes	5986	12	25.0	Mortality	HDP: Any HDP	4	2	3	9
Sharma, 2004(124)	USA	cohort	no	1927	1	NA	SGA	SGA: BW <p10< td=""><td>4</td><td>1</td><td>3</td><td>8</td></p10<>	4	1	3	8
Shin, 2020(125)	Korea	cohort	yes	2174	60	27.1	HDP	HDP: Any HDP	4	2	3	9

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Singareddy, 2021(126)	USA	cohort	no	712	2	29.5	Mortality	CA: Histologic	4	0	3	7
Soliman, 2017(127)	Canada	cohort	yes	303	1	29.0	HDP	HDP: HELLP	4	2	3	9
Soraisham, 2009(128)	Canada	cohort	yes	3094	24	28.9	CA	CA: Clinical	4	2	3	9
Soudée, 2014(129)	France	cohort	no	148	1	28.3	SGA	SGA: BW <p3< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p3<>	4	2	3	9
Stepan, 2015(130)	Czech Republic	cohort	Yes	71	1	30.4	CA	CA: Histologic	4	1	3	8
Strunk, 2012(131)	Australia	cohort	no	838	1	26.9	CA	CA: Histologic	4	2	3	9
Tagere, 2013(132)	India	cohort	yes	87	1	28.5	Mortality	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Tannirwar, 2016(133)	India	cohort	no	496	1	31.5	SGA	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Thomas, 2009(134)	Poland	cohort	yes	42	1	27.3	CA	CA: Histologic	4	0	3	7
Thompson, 1993(135)	South Africa	cohort	yes	235	1	30.4	Mortality	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Tokumasu, 2016(136)	Japan	cohort	no	4496	131	26.0	CA HDP SGA	CA: Clinical HDP: HELLP SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Torchin, 2016(137)	France	cohort	no	2262	447	29.7	HDP SGA	HDP: Any HDP	4	2	3	9
Torrance, 2007(138)	South Africa	cohort	no	187	1	30.4	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Trevisanuto, 2013(139)	Italy	ca-co	yes	98	1	27.8	CA	CA: Histologic	4	2	3	9
Tsai, 2015(140)	Taiwan	ca-co	yes	1680	21	26.0	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Turunen, 2011(141)	Finland	cohort	yes	36	1	26.6	HDP	HDP: PE	4	2	3	9
Upadhyay, 2015(142)	USA	cohort	no	212	1	24.0	Mortality	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7

First author, year	Country	Design	Prospective?	Total infants	Centers	Mean GA cohort (weeks)	Independent variable	Exposure category	Selection	Comparability	Exposure	NOS Total
Ushida, 2020(143)	Japan	cohort	yes	21005	200	28.2	HDP	HDP: Any HDP	4	1	3	8
Van Vliet, 2012(144)	Netherlands	cohort	yes	72	1	29.0	CA	CA: Histologic	4	2	3	9
Vinnars, 2015(145)	Sweden	cohort	yes	167	7	24.5	CA	CA: Histologic	4	2	3	9
Wadhawan, 2007(146)	USA	cohort	no	9461	19	26.1	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Watterberg, 1999(147)	USA	cohort	yes	40	1	25.4	CA	CA: Histologic	4	1	3	8
Westby Wold, 2009(148)	Norway	cohort	no	365	15	30.2	SGA	SGA: BW <p5< td=""><td>4</td><td>1</td><td>3</td><td>8</td></p5<>	4	1	3	8
Wilmink, 2019(149)	Netherlands	cohort	no	273	1	29.3	HDP	HDP: PE	4	2	3	9
Wirbelauer, 2010(150)	Germany	cohort	no	49	1	28.5	SGA	SGA: BW <p10< td=""><td>4</td><td>0</td><td>3</td><td>7</td></p10<>	4	0	3	7
Wocadlo, 1994(151)	Australia	cohort	no	438	1	N	Mortality	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Woo Lim, 2015(152)	South Korea	cohort	no	1649	60	N	Mortality	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9
Xie, 2015(153)	China	cohort	no	371	1	31.1	CA	CA: Histologic	4	2	3	9
Yu, 2011(154)	Korea	cohort	yes	415	1	28.9	SGA	SGA: BW <p3< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p3<>	4	2	3	9
Zanardo, 2010(155)	Italy	cohort	no	287	1	N	CA	CA: Histologic	4	2	3	9
Zaw, 2003(156)	Canada	cohort	no	999	1	24.8	SGA	SGA: BW <p10< td=""><td>4</td><td>2</td><td>3</td><td>9</td></p10<>	4	2	3	9

GA: gestational age; USA: United States of America; HDP: gestational hypertensive disorders, PE: preeclampsia; HELLP: syndrome in pregnancy characterized by hemolysis, elevated liver enzymes and low platelet count; CA: chorioamnionitis; Ca-co: case-control study; SGA: small for gestational age as defined by birth weight percentile; BW: birth weight; P3: 3rd percentile; P5: 5th percentile P10: 10th percentile; IUGR: intra-uterine growth restriction defined on the basis of fetal growth assessment.

Analysis	Criteria for subgrouping		K	OR	95% CI		Р	Heterogeneity		Meta-regression	
					Lower limit	Upper limit		I ² (%)	Р	Р	R ² analog
		Case-control	5	2.059	1.181	3.589	0.011	26.5	0.245	0.181	0.00
	Study type	Cohort	61	1.394	1.222	1.591	< 0.001	67.8	< 0.001		
		Prospective	41	1.404	1.187	1.662	< 0.001	55.3	< 0.001	0.975	0.00
CA		Retrospective	25	1.450	1.182	1.778	< 0.001	76.5	< 0.001		
CA	Marimum CA	GA≤28	13	1.135	0.894	1.441	0.297	70.4	< 0.001	0.017	0.33
	Maximum GA	GA>28	53	1.522	1.340	1.730	< 0.001	47.1	< 0.001		
	Year of study	≤2000	21	1.304	1.011	1.682	0.041	59.5	< 0.001	0.200	0.01
	start	>2000	45	1.485	1.278	1.725	< 0.001	68.1	< 0.001	0.300	0.01
		Case-control	6	1.156	0.703	1.901	0.567	0.00	0.441	0.030	0.06
	Study type	Cohort	36	0.644	0.588	0.705	< 0.001	69.8	< 0.001		
		Prospective	18	0.686	0.553	0.850	0.001	73.6	< 0.001	0.700	0.00
		Retrospective	24	0.653	0.591	0.722	< 0.001	63.2	< 0.001		
IIDI	Manimum CA	GA≤28	11	1.106	0.806	1.518	0.532	62.9	0.003	< 0.001	0.29
	Maximum GA	GA>28	33	0.618	0.565	0.676	< 0.001	66.1	< 0.001		
	Year of study	≤2000	20	0.669	0.571	0.784	< 0.001	67.6	< 0.001	0.606	0.00
	start	>2000	23	0.716	0.617	0.832	< 0.001	77.2	< 0.001	0.000	0.00
		Case-control	5	1.683	1.132	2.500	0.010	37.0	0.175	0.865	0.00
	Study type	Cohort	53	1.609	1.324	1.957	< 0.001	93.6	< 0.001		
SGA/IUGR	5 51	Prospective	19	1.476	0.906	2.404	0.118	96.9	< 0.001	0.406	0.00
		Retrospective	39	1.723	1.480	2.006	< 0.001	82.9	< 0.001		
	Maximum GA	GA≤28	15	2.341	1.813	3.022	< 0.001	81.6	< 0.001	0.055	0.04
	Maximum GA	GA>28	47	1.560	1.242	1.958	< 0.001	93.7	< 0.001		
	Year of study	≤2000	32	1.462	1.100	1.942	0.009	94.4	< 0.001	0.274	0.01
	start	>2000	26	1.786	1.433	2.226	< 0.001	88.8	< 0.001	0.274	0.01

Table 2. Subgroup analysis based on characteristics of the studies.

CA: chorioamnionitis; HDP: hypertensive disorders of pregnancy. SGA: small for gestational age as defined by birth weight percentile; IUGR: intra-uterine growth restriction defined on the basis of fetal growth assessment; GA: gestational age; wks: weeks; K: number of studies; OR: odds ratio; CI: confidence interval; P: p-value; I²: percentage of variation across studies that is due to heterogeneity; R² analog: total between-study variance explained by the moderator.

Association	Covariate	Covariate unit	K	Coefficient	95% CI		Р	R ² analog
					Lower limit	Upper limit		
CA and mortality	MD in GA (exposed minus unexposed)	weeks	54	-0.178	-0.289	-0.068	0.002	0.37
	Median year of cohort	year	61	0.016	-0.003	0.035	0.090	0.12
HDP and mortality	MD in GA (exposed minus unexposed)	weeks	29	-0.249	-0.403	-0.094	0.002	0.17
	Median year of cohort	year	39	0.001	-0.011	0.013	0.884	0.00
SGA/IUGR and mortality	MD in GA (exposed minus unexposed)	weeks	30	-0.282	-0.437	-0.129	< 0.001	0.38
	Median year of cohort	year	57	0.016	-0.007	0.038	0.167	0.00

Table 3. Meta-regression on continuous variables.

CA: chorioamnionitis; HDP: hypertensive disorders of pregnancy. SGA: small for gestational age as defined by birth weight percentile; IUGR: intra-uterine growth restriction defined on the basis of fetal growth assessment; MD: mean difference; GA: gestational age; wks: weeks; OR: odds ratio; RD: risk difference; ACS: antenatal corticosteroids; K: number of studies; CI: confidence interval; P: p-value; R² analog: total between-study variance explained by the moderator.

Analysis	Subgrouping on gestational age	К	OR	95% CI		Р	Heterogeneity		Meta- regression	
	(GA)			Lower limit	Upper limit		I ² (%)	Р	Р	R ² analog
CA	GA significantly lower in CA group	41	1.471	1.281	1.689	< 0.001	61.7	< 0.001	0.432	0.11
	GA not significantly different	9	1.257	0.951	1.662	0.109	0.00	0.897		
HDP	GA significantly higher in HDP group	15	0.611	0.534	0.698	< 0.001	62.7	0.001	0.014	0.00
	GA not significantly different	12	0.884	0.690	1.132	0.329	65.7	0.001		
SGA/IUGR	GA significantly higher in SGA/IUGR group	7	1.245	0.950	1.632	0.112	48.8	0.069	0.025	0.00
	GA not significantly different	19	2.383	1.965	2.889	< 0.001	65.0	< 0.001		

Table 4. Subgroup analysis on gestational age.

CA: chorioamnionitis; HDP: hypertensive disorders of pregnancy. SGA: small for gestational age as defined by birth weight percentile; IUGR: intra-uterine growth restriction defined on the basis of fetal growth assessment; GA: gestational age; wks: weeks; K: number of studies; OR: odds ratio; CI: confidence interval; P: p-value; I²: percentage of variation across studies that is due to heterogeneity; R² analog: total between-study variance explained by the moderator.

Analysis	Continent	K	OR	95% CI		Р	Hetero	geneity	Meta-regression	
				Lower limit	Upper limit		I ² (%)	Р	Р	R ² analog
CA	Asia	14	1.163	0.892	1.515	0.026	47.1	0.012	0.061	0.20
	Oceania	5	1.381	1.126	1.694	0.002	0.00	0.717	0.581	0.00
	Europe	31	1.601	1.294	1.981	< 0.001	70.1	< 0.001	Ref.	
	North America	16	1.368	1.127	1.660	0.002	47.0	0.020	0.356	0.03
HDP	Asia	4	0.753	0.641	0.884	0.001	0.00	0.820	0.123	0.04
	Oceania	2	0.645	0.474	0.878	0.005	0.00	0.913	0.818	0.00
	Europe	15	0.635	0.516	0.781	< 0.001	66.8	< 0.001	Ref.	
	America	19	0.633	0.555	0.721	< 0.001	69.7	< 0.001	0.608	0.00
SGA/IUGR	Asia	9	1.452	1.039	2.029	0.029	87.1	< 0.001	0.330	0.00
	Oceania	5	2.204	1.065	4.561	0.033	93.6	< 0.001	0.722	0.00
	Europe	23	1.867	1.479	2.357	< 0.001	78.2	< 0.001	Ref.	
	North America	19	1.473	1.025	2.117	0.036	96.3	< 0.001	0.222	0.00

Table 5. Subgroup analysis for continent.

CA: chorioamnionitis; HDP: hypertensive disorders of pregnancy. SGA: small for gestational age as defined by birth weight percentile; IUGR: intra-uterine growth retardation defined on the basis of fetal growth assessment; GA: gestational age; wks: weeks; K: number of studies; OR: odds ratio; CI: confidence interval; P: p-value; I²: percentage of variation across studies that is due to heterogeneity. Ref.: reference; R² analog: total between-study variance explained by the moderator.

Analysis	Exposure to antenatal	K	OR	95% CI		Р	Hetero	geneity
	corticosteroids (ACS)			Lower	Upper		I ² (%)	Р
				limit	limit			
CA	Undefined	27	1.282	1.091	1.505	0.005	68.3	< 0.001
	Any	8	1.112	0.806	1.535	0.518	75.5	< 0.001
	Complete course	7	1.042	0.795	1.366	0.764	45.4	0.089
HDP	Undefined	10	1.677	1.382	2.034	< 0.001	69.0	0.001
	Any	10	1.238	0.761	2.017	0.390	98.7	< 0.001
	Complete course	5	1.847	1.232	2.770	0.003	69.4	0.011
SGA/IUGR	Undefined	16	1.258	1.101	1.438	0.001	65.3	< 0.001
	Any	4	1.148	0.960	1.372	0.131	47.3	0.128
	Complete course	9	1.381	0.993	1.920	0.055	88.5	< 0.001

CA: chorioamnionitis; HDP: hypertensive disorders of pregnancy. SGA: small for gestational age as defined by birth weight percentile; IUGR: intra-uterine growth retardation defined on the basis of fetal growth assessment; wks: weeks; K: number of studies; OR: odds ratio; CI: confidence interval; P: p-value; I²: percentage of variation across studies that is due to heterogeneity.

References

Bramer WM, Milic J, Mast F. Reviewing retrieved references for inclusion in systematic 1. reviews using EndNote. J Med Libr Assoc. 2017;105(1):84-7.

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa 2. Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the 3. sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

4. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Subgroup analyses. Introduction to Meta-analysis. 2009:149-86.

Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Identifying and quantifying 5. heterogeneity. Introduction to Meta-analysis. 2009:107-25.

Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Meta-Regression. Introduction to Meta-6. Analysis 2009:187-203.

Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM. Neonatal outcome in 7. severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol. 1999;180(1):221-5.

8. Ahn HM, Park EA, Cho SJ, Kim Y-J, Park H-S. The association of histological chorioamnionitis and antenatal steroids on neonatal outcome in preterm infants born at less than thirtyfour weeks' gestation. Neonatology. 2012;102(4):259-64.

Alexander JM, Gilstrap LC, Cox SM, Leveno KJ. Clinical chorioamnionitis and the prognosis 9. for very low birth weight infants. Obstet Gynecol. 1998;91(5):725-9.

Alfiero Bordigato M, Piva D, Di Gangi IM, Giordano G, Chiandetti L, Filippone M. 10. Asymmetric dimethylarginine in ELBW newborns exposed to chorioamnionitis. Early Hum Dev. 2011;87(2):143-5.

Amin H, Singhal N, Sauve RS. Impact of intrauterine growth restriction on 11. neurodevelopmental and growth outcomes in very low birthweight infants. Acta Paediatr. 1997;86(3):306-14.

12. Arayici S, Kadioglu Simsek G, Oncel MY, Eras Z, Canpolat FE, Oguz SS, et al. The effect of histological chorioamnionitis on the short-term outcome of preterm infants≤ 32 weeks: a single-center study. J Matern Fetal Neonatal Med. 2014;27(11):1129-33.

13. Aslan H, Gul A, Cebeci A. Neonatal outcome in pregnancies after preterm delivery for HELLP syndrome. Gynecol Obstet Invest. 2004;58(2):96-9.

Aucott SW, Donohue PK, Northington FJ. Increased morbidity in severe early intrauterine 14. growth restriction. J Perinatol. 2004;24(7):435-40.

Ausbeck EB, Allman PH, Szychowski JM, Subramaniam A, Katheria A. Neonatal Outcomes 15. at Extreme Prematurity by Gestational Age Versus Birth Weight in a Contemporary Cohort. Am J Perinatol. 2021.

16. Bacak SJ, Baptiste-Roberts K, Amon E, Ireland B, Leet T. Risk factors for neonatal mortality among extremely-low-birth-weight infants. Am J Obstet Gynecol. 2005;192(3):862-7.

Baer RJ, Rogers EE, Partridge JC, Anderson JG, Morris M, Kuppermann M, et al. Population-17. based risks of mortality and preterm morbidity by gestational age and birth weight. J Perinatol. 2016;36(11):1008-13.

18. Bardin C, Zelkowitz P, Papageorgiou A. Outcome of small-for-gestational age and appropriate-for-gestational age infants born before 27 weeks of gestation. Pediatrics. 1997;100(2):E4.

Baud O, Zupan V, Lacaze-Masmonteil T, Audibert F, Shojaei T, Thebaud B, et al. The 19. relationships between antenatal management, the cause of delivery and neonatal outcome in a large cohort of very preterm singleton infants. BJOG. 2000;107(7):877-84.

Been JV, Rours IG, Kornelisse RF, Lima Passos V, Kramer BW, Schneider TA, et al. 20. Histologic chorioamnionitis, fetal involvement, and antenatal steroids: effects on neonatal outcome in preterm infants. Am J Obstet Gynecol. 2009;201(6):587.e1-8.

21. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. Am J Obstet Gynecol. 2000;182(1 Pt 1):198-206.

22. Bolisetty S, Legge N, Bajuk B, Lui K. Preterm infant outcomes in New South Wales and the Australian Capital Territory. J Paediatr Child Health. 2015;51(7):713-21.

23. Bossung V, Fortmann MI, Fusch C, Rausch T, Herting E, Swoboda I, et al. Neonatal Outcome After Preeclampsia and HELLP Syndrome: A Population-Based Cohort Study in Germany. Front Pediatr. 2020;8:579293.

24. Botet F, Figueras J, Carbonell-Estrany X, Arca G, Group CS. Effect of maternal clinical chorioamnionitis on neonatal morbidity in very-low birthweight infants: a case-control study. J Perinat Med. 2010;38(3):269-73.

25. Brodszki J, Morsing E, Malcus P, Thuring A, Ley D, Marsál K. Early intervention in management of very preterm growth-restricted fetuses: 2-year outcome of infants delivered on fetal indication before 30 gestational weeks. Ultrasound Obstet Gynecol. 2009;34(3):288-96.

 Bry K, Jacobsson B, Nilsson S, Bry K. Gastric fluid cytokines are associated with chorioamnionitis and white blood cell counts in preterm infants. Acta Paediatr. 2015;104(6):575-80.
 Candel Pau J, Castillo Salinas F, Perapoch López J, Carrascosa Lezcano A, Sánchez García O, Llurba Olivé E. [Perinatal outcome and cardiac dysfunction in preterm growth-restricted neonates in relation to placental impairment severity]. An Pediatr (Barc). 2016;85(4):170-80.

28. Chard T, Penney G, Chalmers J. The risk of neonatal death in relation to birth weight and maternal hypertensive disease in infants born at 24–32 weeks. Eur J Obstet Gynecol Reprod Biol. 2001;95(1):114-8.

29. Chen XK, Wen SW, Smith G, Yang Q, Walker M. Pregnancy-induced hypertension is associated with lower infant mortality in preterm singletons. BJOG. 2006;113(5):544-51.

30. Cheng S-W, Chou H-C, Tsou K-I, Fang L-J, Tsao P-N. Delivery before 32 weeks of gestation for maternal pre-eclampsia: neonatal outcome and 2-year developmental outcome. Early Hum Dev. 2004;76(1):39-46.

31. Claas MJ, Bruinse HW, van der Heide-Jalving M, Termote JU, de Vries LS. Changes in survival and neonatal morbidity in infants with a birth weight of 750 g or less. Neonatology. 2010;98(3):278-88.

32. Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics. 2000;106(4):659-71.

33. De Felice C, Toti P, Parrini S, Del Vecchio A, Bagnoli F, Latini G, et al. Histologic chorioamnionitis and severity of illness in very low birth weight newborns. Pediatr Crit Care Med. 2005;6(3):298-302.

34. De Jesus LC, Pappas A, Shankaran S, Li L, Das A, Bell EF, et al. Outcomes of small for gestational age infants born at <27 weeks' gestation. J Pediatr. 2013;163(1):55-60.e1-3.

35. de Souza Rugolo LMS, de Sá MPA, Kurokawa CS, Madoglio RJ, Bentlin MR, Jr AR, et al. There is no difference in nitric oxide metabolites and neonatal outcome between premature infants born to pre-eclamptic and those born to normotensive women. Paediatr Int Child Health. 2015;35(1):47-52.

36. Dempsey E, Chen M-F, Kokottis T, Vallerand D, Usher R. Outcome of neonates less than 30 weeks gestation with histologic chorioamnionitis. Obstet Gynecol Surv. 2005;60(10):639-40.

37. Dexter SC, Pinar H, Malee MP, Hogan J, Carpenter MW, Vohr BR. Outcome of very low birth weight infants with histopathologic chorioamnionitis. Obstet Gynecol. 2000;96(2):172-7.
38. Doyle LW. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the

prognosis. Pediatrics. 2001;108(1):134-41.

39. Ecevit A, Anuk-İnce D, Yapakçı E, Kupana-Ayva Ş, Kurt A, Yanık FF, et al. Association of respiratory distress syndrome and perinatal hypoxia with histologic chorioamnionitis in preterm infants. Turk J Pediatr. 2014;56(1):56-61.

40. El Ayoubi M, Jarreau PH, Van Reempts P, Cuttini M, Kaminski M, Zeitlin J. Does the antenatal detection of fetal growth restriction (FGR) have a prognostic value for mortality and short-term morbidity for very preterm infants? Results from the MOSAIC cohort. J Matern Fetal Neonatal Med. 2016;29(4):596-601.

41. El-Metwally D, Vohr B, Tucker R. Survival and neonatal morbidity at the limits of viability in the mid 1990s: 22 to 25 weeks. J Pediatr. 2000;137(5):616-22.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

42. Erdemir G, Kultursay N, Calkavur S, Zekioğlu O, Koroglu OA, Cakmak B, et al. Histological chorioamnionitis: effects on premature delivery and neonatal prognosis. Pediatr Neonatol. 2013;54(4):267-74.

43. Ferdynus C, Quantin C, Abrahamowicz M, Platt R, Burguet A, Sagot P, et al. Can birth weight standards based on healthy populations improve the identification of small-for-gestational-age newborns at risk of adverse neonatal outcomes? Pediatrics. 2009;123(2):723-30.

44. Fernandez-Rodriguez B, de Alba C, Villalain C, Pallás CR, Galindo A, Herraiz I. Obstetric and pediatric growth charts for the detection of fetal growth restriction and neonatal adverse outcomes in preterm newborns before 34 weeks of gestation. J Matern Fetal Neonatal Med. 2021;34(7):1112-9.

45. Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol. 1995;172(6):1785-92.

46. Fukami T, Yoshizato T, Mori T, Yukitake K, Miyake Y, Kawarabayashi T. Obstetrical factors for death and brain injury among extremely-low-birth-weight infants. J Perinat Med. 2007;35(6):543-9.

47. Fung G, Bawden K, Chow P, Yu V. Long-term Outcome of Extremely Preterm Infants Following Chorioamnionitis. HK J Paediatr. 2003;8(2):87-92.

48. Gagliardi L, Rusconi F, Da Frè M, Mello G, Carnielli V, Di Lallo D, et al. Pregnancy disorders leading to very preterm birth influence neonatal outcomes: results of the population-based ACTION cohort study. Pediatr Res. 2013;73(6):794-801.

49. Gagliardi L, Rusconi F, Bellù R, Zanini R. Association of maternal hypertension and chorioamnionitis with preterm outcomes. Pediatrics. 2014;134(1):e154-61.

50. García-Muñoz Rodrigo F, Galán Henríquez G, Figueras Aloy J, García-Alix Pérez A. Outcomes of very-low-birth-weight infants exposed to maternal clinical chorioamnionitis: a multicentre study. Neonatology. 2014;106(3):229-34.

51. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am J Obstet Gynecol. 2004;191(2):481-7.

52. Gemmell L, Martin L, Murphy K, Modi N, Håkansson S, Reichman B, et al. Hypertensive disorders of pregnancy and outcomes of preterm infants of 24 to 28 weeks' gestation. J Perinatol. 2016;36(12):1067-72.

53. Giapros V, Drougia A, Krallis N, Theocharis P, Andronikou S. Morbidity and mortality patterns in small-for-gestational age infants born preterm. J Matern Fetal Neonatal Med. 2012;25(2):153-7.

54. González-Luis G, García J, Rodríguez-Miguélez J. Neonatal morbidity and mortality in very low birth weight infants according to exposure to chorioamnionitis. An Esp Pediatr. 2002;56(6):551-5.
55. Gortner L, Wauer RR, Stock GJ, Reiter HL, Reiss I, Jorch G, et al. Neonatal outcome in small

for gestational age infants: do they really better? J Perinat Med. 1999;27(6):484-9.
56. Gray PH, Hurley TM, Rogers YM, O'Callaghan MJ, Tudehope DI, Burns YR, et al. Survival and neonatal and neurodevelopmental outcome of 24–29 week gestation infants according to primary

cause of preterm delivery. Aust N Z J Obstet Gynaecol. 1997;37(2):161-8.

57. Grill A, Olischar M, Weber M, Pollak A, Leitich H. Type of delivery onset has a significant impact on post-natal mortality in preterm infants of less than 30 weeks' gestation. Acta Paediatr. 2014;103(7):722-6.

58. Grisaru-Granovsky S, Reichman B, Lerner-Geva L, Boyko V, Hammerman C, Samueloff A, et al. Mortality and morbidity in preterm small-for-gestational-age infants: a population-based study. Am J Obstet Gynecol. 2012;206(2):150.e1-7.

59. Hartung J, Kalache KD, Heyna C, Heling KS, Kuhlig M, Wauer R, et al. Outcome of 60 neonates who had ARED flow prenatally compared with a matched control group of appropriate-for-gestational age preterm neonates. Ultrasound Obstet Gynecol. 2005;25(6):566-72.

60. Hendson L, Russell L, Robertson CM, Liang Y, Chen Y, Abdalla A, et al. Neonatal and neurodevelopmental outcomes of very low birth weight infants with histologic chorioamnionitis. J Pediatr. 2011;158(3):397-402.

61. Hentges CR, Silveira RC, Ferrelli RS, Procianoy RS. Influence of maternal pre-eclampsia on VEGF/PIGF heterodimer levels in preterm infants. J Matern Fetal Neonatal Med. 2015;28(18):2166-71.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

62. Hiett A, Brown H, Britton K. Outcome of infants delivered between 24 and 28 weeks' gestation in women with severe pre-eclampsia. J Matern Fetal Med. 2001;10(5):301-4.

63. Holcroft CJ, Askin FB, Patra A, Allen MC, Blakemore KJ, Graham EM. Are histopathologic chorioamnionitis and funisitis associated with metabolic acidosis in the preterm fetus? Am J Obstet Gynecol. 2004;191(6):2010-5.

64. Holtrop PC, Ertzbischoff LM, Roberts CL, Batton DG, Lorenz RP. Survival and short-term outcome in newborns of 23 to 25 weeks' gestation. Am J Obstet Gynecol. 1994;170(5):1266-70.

65. Hong S, Jeong M, Oh S, Oh JW, Park CW, Park JS, et al. Funisitis as a Risk Factor for Adverse Neonatal Outcomes in Twin Neonates with Spontaneous Preterm Birth: A Retrospective Cohort Study. Yonsei Med J. 2021;62(9):822-8.

66. Jelin AC, Cheng YW, Shaffer BL, Kaimal AJ, Little SE, Caughey AB. Early-onset preeclampsia and neonatal outcomes. J Matern Fetal Neonatal Med. 2010;23(5):389-92.

67. Jensen EA, Foglia EE, Dysart KC, Simmons RA, Aghai ZH, Cook A, et al. Adverse effects of small for gestational age differ by gestational week among very preterm infants. Arch Dis Child Fetal Neonatal Ed. 2019;104(2):F192-f8.

68. Kent A, Lomas F, Hurrion E, Dahlstrom JE. Antenatal steroids may reduce adverse neurological outcome following chorioamnionitis: neurodevelopmental outcome and chorioamnionitis in premature infants. J Paediatr Child Health. 2005;41(4):186-90.

69. Kent AL, Wright IM, Abdel-Latif ME. Mortality and adverse neurologic outcomes are greater in preterm male infants. Pediatrics. 2012;129(1):124-31.

70. Kilbride HW, Daily DK, Claflin K, Hall RT, Maulik D, Grundy HO. Improved survival and neurodevelopmental outcome for infants less than 801 grams birthweight. Am J Perinatol. 1990;7(02):160-5.

71. Kim CR, Vohr BR, Oh W. Effects of maternal hypertension in very-low-birth-weight infants. Arch Pediatr Adolesc Med. 1996;150(7):686-91.

72. Kim SY, Choi CW, Jung E, Lee J, Lee JA, Kim H, et al. Neonatal morbidities associated with histologic chorioamnionitis defined based on the site and extent of inflammation in very low birth weight infants. J Korean Med Sci. 2015;30(10):1476.

73. Lal MK, Manktelow BN, Draper ES, Field DJ. Chronic lung disease of prematurity and intrauterine growth retardation: a population-based study. Pediatrics. 2003;111(3):483-7.

74. Lee MJ, Conner EL, Charafeddine L, Woods JR, Jr., Del Priore G. A critical birth weight and other determinants of survival for infants with severe intrauterine growth restriction. Ann N Y Acad Sci. 2001;943:326-39.

75. Lee SY, Ng DK, Fung GP, Chow CB, Shek CC, Tang PM, et al. Chorioamnionitis with or without funisitis increases the risk of hypotension in very low birthweight infants on the first postnatal day but not later. Arch Dis Child Fetal Neonatal Ed. 2006;91(5):F346-8.

76. Lee Y, Kim H-J, Choi S-J, Oh S-y, Kim J-S, Roh C-R, et al. Is there a stepwise increase in neonatal morbidities according to histological stage (or grade) of acute chorioamnionitis and funisitis?: effect of gestational age at delivery. J Perinat Med. 2015;43(2):259-67.

77. Lee H-S, Kim SY. Histological chorioamnionitis, antenatal steroids, and neonatal outcomes in very low birth weight infants: A nationwide study. PLoS One. 2019;14(10):e0224450.

78. Ley D, Wide-Swensson D, Lindroth M, Svenningsen N, Marsal K. Respiratory distress syndrome in infants with impaired intrauterine growth. Acta Paediatr. 1997;86(10):1090-6.

79. Liu Z, Tang Z, Li J, Yang Y. Effects of placental inflammation on neonatal outcome in preterm infants. Pediatr Neonatol. 2014;55(1):35-40.

80. Liu P-C, Hung Y-L, Shen C-M, Chen P-C, Hsieh W-S. Histological chorioamnionitis and its impact on respiratory outcome in very-low-birth-weight preterm infants. Pediatr Neonatol. 2021.
81. Locatelli A, Roncaglia N, Andreotti C, Doria V, Doni D, Pezzullo JC, et al. Factors affecting

survival in infants weighing 750 g or less. Eur J Obstet Gynecol Reprod Biol. 2005;123(1):52-5.
82. Lucey JF, Rowan CA, Shiono P, Wilkinson AR, Kilpatrick S, Payne NR, et al. Fetal infants:

the fate of 4172 infants with birth weights of 401 to 500 grams—the Vermont Oxford Network experience (1996–2000). Pediatrics. 2004;113(6):1559-66.

83. Madoglio R, Rugolo L, Kurokawa C, Sa M, Lyra J, Antunes L. Inflammatory and oxidative stress airway markers in premature newborns of hypertensive mothers. Braz J Med Biol Res. 2016;49(9).

84. Maisonneuve E, Lorthe E, Torchin H, Delorme P, Devisme L, L'Hélias LF, et al. Association of Chorioamnionitis with Cerebral Palsy at Two Years after Spontaneous Very Preterm Birth: The EPIPAGE-2 Cohort Study. J Pediatr. 2020;222:71-8.e6.

85. Malhotra A, Yahya Z, Sasi A, Jenkin G, Ditchfield M, Polglase GR, et al. Does fetal growth restriction lead to increased brain injury as detected by neonatal cranial ultrasound in premature infants? J Paediatr Child Health. 2015;51(11):1103-8.

86. Markestad T, Kaaresen PI, Rønnestad A, Reigstad H, Lossius K, Medbø S, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics. 2005;115(5):1289-98.

87. Matić M, Inati V, Abdel-Latif ME, Kent AL, Network NAN. Maternal hypertensive disorders are associated with increased use of respiratory support but not chronic lung disease or poorer neurodevelopmental outcomes in preterm neonates at< 29 weeks of gestation. J Paediatr Child Health. 2017;53(4):391-8.

McBride CA, Bernstein IM, Badger GJ, Horbar JD, Soll RF. The effect of maternal hypertension on mortality in infants 22, 29weeks gestation. Pregnancy Hypertens. 2015;5(4):362-6.
Melamed N, Pittini A, Barrett J, Shah J, Yoon EW, Lemyre B, et al. Antenatal Corticosteroids

and Outcomes of Small-for-Gestational-Age Neonates. Obstet Gynecol. 2016;128(5):1001-8.
90. Monier I, Ancel PY, Ego A, Jarreau PH, Lebeaux C, Kaminski M, et al. Fetal and neonatal

outcomes of preterm infants born before 32 weeks of gestation according to antenatal vs postnatal assessments of restricted growth. Am J Obstet Gynecol. 2017;216(5):516.e1-.e10.

91. Mu S-C, Lin C-H, Chen Y-L, Ma H-J, Lee J-S, Lin M-I, et al. Impact on neonatal outcome and anthropometric growth in very low birth weight infants with histological chorioamnionitis. J Formos Med Assoc. 2008;107(4):304-10.

92. Nasef N, Shabaan AE, Schurr P, Iaboni D, Choudhury J, Church P, et al. Effect of clinical and histological chorioamnionitis on the outcome of preterm infants. Am J Perinatol. 2013;30(01):059-68.
93. Natarajan G, Glibetic M, Thomas RL, Aranda JV. Chorioamnionitis and ontogeny of

circulating prostaglandin and thromboxane in preterm infants. Am J Perinatol. 2008;25(08):491-7.
94. Nayeri UA, Buhimschi CS, Zhao G, Buhimschi IA, Bhandari V. Components of the

antepartum, intrapartum, and postpartum exposome impact on distinct short-term adverse neonatal outcomes of premature infants: A prospective cohort study. PLoS One. 2018;13(12):e0207298.

95. Nicaise C, Gire C, Fagianelli P, Debriere R, Thomachot L, d'Ercole C, et al. [Neonatal consequences of preterm premature rupture of membrane (PPROM) at 24-34 WG: 118 singleton pregnancies]. J Gynecol Obstet Biol Reprod (Paris). 2002;31(8):747-54.

96. Nobile S, Marchionni P, Carnielli VP. Neonatal outcome of small for gestational age preterm infants. Eur J Pediatr. 2017;176(8):1083-8.

97. Ogunyemi D, Murillo M, Jackson U, Hunter N, Alperson B. The relationship between placental histopathology findings and perinatal outcome in preterm infants. J Matern Fetal Neonatal Med. 2003;13(2):102-9.

98. Oh S-H, Kim J-j, Do H-j, Lee BS, Kim K-S, Kim EA-R. Preliminary Study on Neurodevelopmental Outcome and Placental Pathology among Extremely Low Birth Weight Infants. Korean J Perinatol. 2015;26(1):67-77.

99. Palta M, Sadek M, Gabbert D, Brady W, Weinstein MR, McGuinness G, et al. The relation of maternal complications to outcomes in very low birthweight infants in an era of changing neonatal care. Am J Perinatol. 1996;13(02):109-14.

100. Pappas A, Kendrick DE, Shankaran S, Stoll BJ, Bell EF, Laptook AR, et al. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. JAMA pediatrics. 2014;168(2):137-47.

101. Park YH, Lee GM, Yoon JM, Cheon EJ, Ko KO, Lee YH, et al. Effect of early postnatal neutropenia in very low birth weight infants born to mothers with pregnancy-induced hypertension. Korean J Pediatr. 2012;55(12):462.

102. Park JW, Park KH, Jung EY. Clinical significance of histologic chorioamnionitis with a negative amniotic fluid culture in patients with preterm labor and premature membrane rupture. PLoS One. 2017;12(3):e0173312.

103. Pietrasanta C, Pugni L, Merlo D, Acaia B, Consonni D, Ronchi A, et al. Impact of different stages of intrauterine inflammation on outcome of preterm neonates: Gestational age-dependent and-independent effect. PLoS One. 2019;14(2):e0211484.

104. Piper JM, Xenakis EM, McFarland M, Elliott BD, Berkus MD, Langer O. Do growth-retarded premature infants have different rates of perinatal morbidity and mortality than appropriately grown premature infants? Obstet Gynecol. 1996;87(2):169-74.

105. Plakkal N, Soraisham AS, Trevenen C, Freiheit E, Sauve R. Histological chorioamnionitis and bronchopulmonary dysplasia: a retrospective cohort study. J Perinatol. 2013;33(6):441-5.

106. Procianoy RS, Silveira RC, Mussi-Pinhata MM, Souza Rugolo LM, Leone CR, de Andrade Lopes JM, et al. Sepsis and neutropenia in very low birth weight infants delivered of mothers with preeclampsia. J Pediatr. 2010;157(3):434-8, 8.e1.

107. Puri K, Taft DH, Ambalavanan N, Schibler KR, Morrow AL, Kallapur SG. Association of Chorioamnionitis with Aberrant Neonatal Gut Colonization and Adverse Clinical Outcomes. PLoS One. 2016;11(9):e0162734.

108. Rakza T, Magnenant E, Klosowski S, Tourneux P, Bachiri A, Storme L. Early hemodynamic consequences of patent ductus arteriosus in preterm infants with intrauterine growth restriction. J Pediatr. 2007;151(6):624-8.

109. Ray JG, Park AL, Fell DB. Mortality in infants affected by preterm birth and severe small-forgestational age birth weight. Pediatrics. 2017;140(6).

110. Razak A, Patel W, Durrani N, McDonald SD, Vanniyasingam T, Thabane L, et al. Neonatal respiratory outcomes in pregnancy induced hypertension: introducing a novel index. J Matern Fetal Neonatal Med. 2020;33(4):625-32.

111. Regev RH, Arnon S, Litmanovitz I, Bauer-Rusek S, Boyko V, Lerner-Geva L, et al. Outcome of singleton preterm small for gestational age infants born to mothers with pregnancy-induced hypertension. A population-based study. J Matern Fetal Neonatal Med. 2015;28(6):666-73.

112. Reiss I, Landmann E, Heckmann M, Misselwitz B, Gortner L. Increased risk of bronchopulmonary dysplasia and increased mortality in very preterm infants being small for gestational age. Arch Gynecol Obstet. 2003;269(1):40-4.

113. Richardson BS, Wakim E, Walton J. Preterm histologic chorioamnionitis: impact on cord gas and pH values and neonatal outcome. Am J Obstet Gynecol. 2006;195(5):1357-65.

114. Rocha G, Proença E, Quintas C, Rodrigues T, Guimarães H. Chorioamnionitis and neonatal morbidity. Acta Med Port. 2006;19(3):207-12.

115. Rocha G, de Lima FF, Machado AP, Guimaraes H. Preeclampsia predicts higher incidence of bronchopulmonary dysplasia. J Perinatol. 2018;38(9):1165-73.

116. Rodríguez-Trujillo A, Cobo T, Vives I, Bosch J, Kacerovsky M, Posadas DE, et al. Gestational age is more important for short-term neonatal outcome than microbial invasion of the amniotic cavity or intra-amniotic inflammation in preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand. 2016;95(8):926-33.

117. Ryan E, Eves D, Menon PJ, Alnafisee S, Mooney EE, Downey P, et al. Histological chorioamnionitis is predicted by early infant C-reactive protein in preterm infants and correlates with neonatal outcomes. Acta Paediatr. 2020;109(4):720-7.

118. Sabino AT, Souza Ed, Goulart AL, Lima AMd, Sass N. High blood pressure during pregnancy is not a protective factor for preterm infants with very low birth weight. A case-control study. Rev Bras Ginecol Obstet. 2017;39(4):155-61.

119. Sadeghi Moghaddam P, Aghaali M. Survival of 798 low birth weight infants according to birth weight and gestational age. Shiraz E Med J. 2015;16(11-12).

120. Salas AA, Faye-Petersen OM, Sims B, Peralta-Carcelen M, Reilly SD, McGwin G, Jr., et al. Histological characteristics of the fetal inflammatory response associated with neurodevelopmental impairment and death in extremely preterm infants. J Pediatr. 2013;163(3):652-7.e1-2.

121. Serenius F, Ewald U, Farooqi A, Holmgren PA, Håkansson S, Sedin G. Short-term outcome after active perinatal management at 23-25 weeks of gestation. A study from two Swedish tertiary care centres. Part 2: infant survival. Acta Paediatr. 2004;93(8):1081-9.

122. Shah PS, Xiang YY, Synnes A, Rouvinez-Bouali N, Yee W, Lee SK. Prediction of survival without morbidity for infants born at under 33 weeks gestational age: a user-friendly graphical tool. Arch Dis Child Fetal Neonatal Ed. 2012;97(2):F110-F5.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

123. Shankaran S, Fanaroff AA, Wright LL, Stevenson DK, Donovan EF, Ehrenkranz RA, et al. Risk factors for early death among extremely low-birth-weight infants. Am J Obstet Gynecol. 2002;186(4):796-802.

124. Sharma P, McKay K, Rosenkrantz TS, Hussain N. Comparisons of mortality and predischarge respiratory outcomes in small-for-gestational-age and appropriate-for-gestational-age premature infants. BMC Pediatr. 2004;4:9.

125. Shin SH, Shin SH, Kim SH, Kim Y-J, Cho H, Kim E-K, et al. The Association of Pregnancyinduced Hypertension with Bronchopulmonary Dysplasia–A Retrospective Study Based on the Korean Neonatal Network database. Sci Rep. 2020;10(1):1-6.

126. Singareddy A, Lee ASE, Sweeney PL, Finkle AE, Williams HL, Buchanan PM, et al. Elevated neutrophil-lymphocyte ratios in extremely preterm neonates with histologic chorioamnionitis. J Perinatol. 2021;41(6):1269-77.

Soliman N, Chaput K, Alshaikh B, Yusuf K. Preeclampsia and the Risk of Bronchopulmonary Dysplasia in Preterm Infants Less Than 32 Weeks' Gestation. Am J Perinatol. 2017;34(6):585-92.
Soraisham AS, Singhal N, McMillan DD, Sauve RS, Lee SK. A multicenter study on the

clinical outcome of chorioamnionitis in preterm infants. Am J Obstet Gynecol. 2009;200(4):372.e1-6. 129. Soudée S, Vuillemin L, Alberti C, Mohamed D, Becquet O, Farnoux C, et al. Fetal growth restriction is worse than extreme prematurity for the developing lung. Neonatology. 2014;106(4):304-10.

130. Stepan M, Cobo T, Maly J, Navratilova M, Musilova I, Hornychova H, et al. Neonatal outcomes in subgroups of women with preterm prelabor rupture of membranes before 34 weeks. J Matern Fetal Neonatal Med. 2016;29(14):2373-7.

131. Strunk T, Doherty D, Jacques A, Simmer K, Richmond P, Kohan R, et al. Histologic chorioamnionitis is associated with reduced risk of late-onset sepsis in preterm infants. Pediatrics. 2012;129(1):e134-41.

132. Tagare A, Chaudhari S, Kadam S, Vaidya U, Pandit A, Sayyad MG. Mortality and morbidity in extremely low birth weight (ELBW) infants in a neonatal intensive care unit. Indian J Pediatr. 2013;80(1):16-20.

133. Tannirwar S, Kadam S, Pandit A, Vaidya U, Parikh T, Ankit S. Comparisons of mortality and pre-discharge respiratory morbidities in small for gestational age and appropriate-for gestational age premature infants-An Indian Experience. Iran J Neonatol. 2016;7(4):1-6.

134. Thomas W, Seidenspinner S, Kramer BW, Kawczyńska-Leda N, Chmielnicka-Kopaczyk M, Marx A, et al. Airway concentrations of angiopoietin-1 and endostatin in ventilated extremely premature infants are decreased after funisitis and unbalanced with bronchopulmonary dysplasia/death. Pediatr Res. 2009;65(4):468-73.

135. Thompson CM, Buccimazza SS, Webster J, Malan AF, Molteno CD. Infants of less than 1250 grams birth weight at Groote Schuur Hospital: outcome at 1 and 2 years of age. Pediatrics. 1993;91(5):961-8.

136. Tokumasu H, Tokumasu S, Kawakami K. Impact of pre-eclampsia in extremely premature infants: Population-based study. Pediatr Int. 2016;58(7):578-83.

137. Torchin H, Ancel PY, Goffinet F, Hascoët JM, Truffert P, Tran D, et al. Placental Complications and Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort Study. Pediatrics. 2016;137(3):e20152163.

138. Torrance HL, Mulder EJ, Brouwers HA, van Bel F, Visser GH. Respiratory outcome in preterm small for gestational age fetuses with or without abnormal umbilical artery Doppler and/or maternal hypertension. J Matern Fetal Neonatal Med. 2007;20(8):613-21.

139. Trevisanuto D, Peruzzetto C, Cavallin F, Vedovato S, Cosmi E, Visentin S, et al. Fetal placental inflammation is associated with poor neonatal growth of preterm infants: a case-control study. J Matern Fetal Neonatal Med. 2013;26(15):1484-90.

140. Tsai LY, Chen YL, Tsou KI, Mu SC. The impact of small-for-gestational-age on neonatal outcome among very-low-birth-weight infants. Pediatr Neonatol. 2015;56(2):101-7.

141. Turunen R, Andersson S, Laivuori H, Kajantie E, Siitonen S, Repo H, et al. Increased postnatal inflammation in mechanically ventilated preterm infants born to mothers with early-onset preeclampsia. Neonatology. 2011;100(3):241-7.

142. Upadhyay K, Pourcyrous M, Dhanireddy R, Talati A. Outcomes of neonates with birth weight ≤ 500 g: a 20-year experience. J Perinatol. 2015;35(9):768-72.

143. Ushida T, Kotani T, Hayakawa M, Hirakawa A, Sadachi R, Nakamura N, et al. Antenatal corticosteroids and preterm offspring outcomes in hypertensive disorders of pregnancy: A Japanese cohort study. Sci Rep. 2020;10(1):1-10.

van Vliet EO, de Kieviet JF, van der Voorn JP, Been JV, Oosterlaan J, van Elburg RM. 144. Placental pathology and long-term neurodevelopment of very preterm infants. Am J Obstet Gynecol. 2012;206(6):489.e1-7.

Vinnars MT, Papadogiannakis N, Nasiell J, Holmström G, Westgren M. Placental pathology 145. in relation to stillbirth and neonatal outcome in an extremely preterm population: a prospective cohort study. Acta Obstet Gynecol Scand. 2015;94(6):584-90.

Wadhawan R, Oh W, Perritt R, Laptook AR, Poole K, Wright LL, et al. Association between 146. early postnatal weight loss and death or BPD in small and appropriate for gestational age extremely low-birth-weight infants. J Perinatol. 2007;27(6):359-64.

147. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104(6):1258-63. Westby Wold SH, Sommerfelt K, Reigstad H, Rønnestad A, Medbø S, Farstad T, et al. 148.

Neonatal mortality and morbidity in extremely preterm small for gestational age infants: a population based study. Arch Dis Child Fetal Neonatal Ed. 2009;94(5):F363-7.

Wilmink FA, Reijnierse J, Reiss IKM, Steegers EAP, de Jonge RCJ. Preeclampsia and risk of 149. developing bronchopulmonary dysplasia in very preterm neonates. Pregnancy Hypertens. 2019;15:57-63.

150. Wirbelauer J, Thomas W, Rieger L, Speer CP. Intrauterine growth retardation in preterm infants \leq 32 weeks of gestation is associated with low white blood cell counts. Am J Perinatol. 2010;27(10):819-24.

151. Wocadlo C, Rieger I. Developmental outcome at 12 months corrected age for infants born less than 30 weeks gestation: influence of reduced intrauterine and postnatal growth. Early Hum Dev. 1994;39(2):127-37.

152. Woo Lim J, Chung S-H, Kang DR, Kim C-R. Risk factors for cause-specific mortality of very-low-birth-weight infants in the Korean Neonatal Network. J Korean Med Sci. 2015;30(Suppl 1):S35-S44.

Xie A, Zhang W, Chen M, Wang Y, Wang Y, Zhou Q, et al. Related factors and adverse 153. neonatal outcomes in women with preterm premature rupture of membranes complicated by histologic chorioamnionitis. Med Sci Monit. 2015;21:390-5.

154. Yu HJ, Kim ES, Kim JK, Yoo HS, Ahn SY, Chang YS, et al. Outcomes of small for gestational age micropremies depending on how young or how small they are. Korean J Pediatr. 2011;54(6):246-52.

155. Zanardo V, Vedovato S, Cosmi E, Litta P, Cavallin F, Trevisanuto D, et al. Preterm premature rupture of membranes, chorioamnion inflammatory scores and neonatal respiratory outcome. BJOG. 2010;117(1):94-8.

156. Zaw W, Gagnon R, da Silva O. The risks of adverse neonatal outcome among preterm small for gestational age infants according to neonatal versus fetal growth standards. Pediatrics. 2003;111(6 Pt 1):1273-7.

MOOSE Checklist for Meta-analyses of Observational Studies

Item No	Recommendation	Reported on Page No
Reporting o	f background should include	
1	Problem definition	3-4
2	Hypothesis statement	-
3	Description of study outcome(s)	4-5
4	Type of exposure or intervention used	4
5	Type of study designs used	4, Suppl (page 3-4)
6	Study population	4
Reporting o	f search strategy should include	
7	Qualifications of searchers (eg, librarians and investigators)	Title page, Suppl (page 3)
8	Search strategy, including time period included in the synthesis and key words	4, Suppl (pages 1-3)
9	Effort to include all available studies, including contact with authors	4, Suppl (page 4)
10	Databases and registries searched	4
11	Search software used, name and version, including special features used (eg, explosion)	Suppl (page3)
12	Use of hand searching (eg, reference lists of obtained articles)	Suppl (page 3)
13	List of citations located and those excluded, including justification	Suppl Table 1, Suppl Fig 1
14	Method of addressing articles published in languages other than English	Suppl (page3)
15	Method of handling abstracts and unpublished studies	Suppl (page3)
16	Description of any contact with authors	Suppl (page 4)
Reporting o	f methods should include	
17	Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	4
18	Rationale for the selection and coding of data (eg, sound clinical principles or convenience)	4
19	Documentation of how data were classified and coded (eg, multiple raters, blinding and interrater reliability)	4
20	Assessment of confounding (eg, comparability of cases and controls in studies where appropriate)	4
21	Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results	4
22	Assessment of heterogeneity	4-5
23	Description of statistical methods (eg, complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated	4-5 Suppl (pages 3-4)
24	Provision of appropriate tables and graphics	Table 1 Suppl tables 1-6 Figs 1-3 Suppl Figs 1-8

Reporting of results should include								
25	Graphic summarizing individual study estimates and overall estimate	Figs 1-2 Suppl Figs 2-7						
26	Table giving descriptive information for each study included	Suppl Table 1						
27	Results of sensitivity testing (eg, subgroup analysis)	Fig 1-2, Suppl Figs 2-7 Suppl Tables 2, 4 and 5						
28	Indication of statistical uncertainty of findings	Figs 1-2 Suppl Figs 2-7						

Item No	Recommendation							
Reporting of discussion should include								
29	Quantitative assessment of bias (eg, publication bias)	8, Suppl Fig 8						
30	Justification for exclusion (eg, exclusion of non-English language citations)	Suppl (page 3)						
31	Assessment of quality of included studies	Suppl Table 1						
Reporting of	Reporting of conclusions should include							
32	Consideration of alternative explanations for observed results	7-10						
33	Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)	7-10						
34	Guidelines for future research	7-10						
35	Disclosure of funding source	11						

From: Stroup DF, Berlin JA, Morton SC, et al, for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of Observational Studies in Epidemiology. A Proposal for Reporting. JAMA. 2000;283(15):2008-2012. doi: 10.1001/jama.283.15.2008.